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ABSTRACT 
 
The amphotericin B (AmB) is a drug of peculiar physicochemical features: being 
amphiphilic and amphoteric. These characteristics turn difficult the drug load into 
therapeutic systems. AmB is currently available in the market as micelles, liposomes and 
lipid complex for injection. The literature show that there is an intimate correlation 
between the AmB bound to the carrier and its biological response. However, there is a 
deficiency concerning the physicochemical characterization of the available AmB-
containing products. Therefore, the aim of this work was to characterize AmB-containing 
carriers seeking a prediction to its biological response. The AmB-containing micellar 
system was the first product available for clinical use. The patent of this product has 
already expired some years ago. In this work we have characterized the original system 
and two other similar micellar products. In addition, we studied the stability increase of 
heated systems, by the formation of AmB “super-aggregates”. AmBisome®, an AmB-
containing liposomal system, was also characterized and, for the first time, tested  for the 
possibility of super-aggregates formation. The AmB incorporation into nano and 
microemulsion systems was presented and the physicochemical characteristics evaluated, 
focusing mainly on applications for the treatment of fungal ocular diseases and also for 
visceral leishmaniasis. The main techniques used for characterization were electronic 
spectroscopy, circular dichroism and dynamic light scattering. The isothermal titration 
calorimetry (ITC) was used as an attempt to measuring the super-aggregates energy 
formation. Besides, an AmB soluble derivative was developed and characterized by 
atomic mass spectroscopy, infra-red, UV-Vis and circular dichroism. Then, this AmB-
derivative was loaded into a microemulsion as a vehiculation strategy. The overall results 
show that the AmB-containing systems presented different molecular aggregation states 
that depends on the carrier, the way the drug is incorporated and also on the diluent. 
According to the literature, the aggregation state is associated with both, drug efficiency 
and toxicity. In nanoemulsion systems, the drug is found aggregated and multi-
aggregated. In microemulsions, AmB is loaded as monomers. The heated micellar 
systems form AmB super-aggregates while the liposomal system is unable to form such 
molecular structure. Moreover, the AmB soluble derivative presented distinct features 
when compared to the original molecule. However, once incorporated into the 
microemulsion, the aggregation state is similar to that of the original AmB molecule, as 
  
 
supported by UV-Vis and circular dichroism results. It can be concluded that the AmB 
aggregation state varies according to the kind of carrier, the drug concentration and also 
the way of drug incorporation, even into one same carrier. Finally, the soluble derivative 
opens the possibility for drug carrying into aqueous vehicles for the treatment of many 
diseases by different administration routes. 
  
 
RESUMO 
 
A anfotericina B (AmB) é um fármaco de características físico-químicas bastante 
peculiares: de caráter anfifílico e anfotérico. Essas características tornam difícil sua 
veiculação em sistemas terapêuticos. Atualmente, a AmB é veiculada por via intravenosa 
nas formas de micelas, lipossomas e complexos lipídicos. A literatura demonstra que 
existe uma íntima relação entre a forma como a AmB está complexada ao sistema 
carreador e sua resposta biológica. Entretanto, há uma deficiência nos dados de 
caracterização fisico-química dos produtos disponíveis contendo AmB. Portanto, o 
objetivo deste trabalho foi realizar a caracterização físico-química de sistemas 
carreadores de AmB visando uma predição de sua resposta biológica. Os sistemas 
micelares de AmB foram os primeiros produtos disponíveis à prática clínica, de forma 
que sua patente expirou há alguns anos. Neste trabalho, o sistema original e dois de seus 
similares foram caracterizados e o aumento da estabilidade destes sistemas após 
aquecimento, pela formação dos super-agregados de AmB foi estudado. O sistema 
liposomal AmBisome® também foi caracterizado e, pela primeira vez, foi estudada a 
possibilidade de super-agregação, a exemplo dos sistemas micelares, a partir de 
lipossomas. A incorporação de AmB em sistemas nano e microemulsionados foi 
apresentada e as características físico-químicas destes sistemas foram estudados, com 
demonstração de suas aplicações no tratamento ocular de infecções fúngicas e também 
para o tratamento de leishmaniose visceral. As principais técnicas de caracterização 
aplicadas foram espectroscopia UV-Vis, dicroísmo circular e espalhamento dinâmico de 
luz. A técnica de calorimetria de titulação isotérmica (ITC) foi utilizada numa tentativa 
de medir a energia de formação dos superagregados. Adicionalmente, um derivado 
solúvel de AmB foi desenvolvido e caracterizado por espectroscopia de massa atômica, 
infra-vermelho, UV-Vis e dicroísmo circular, bem como incorporado em sistema 
microemulsionado como estratégia de veiculação deste derivado solúvel. Os resultados 
revelam que os sistemas contendo AmB apresentam diferentes formas de agregação 
molecular dependendo do carreador, da forma de incorporação do fármaco e do diluente 
empregado para redispersar o sistema. Segundo a literatura, o estado de agregação está 
intimamente ligado à eficácia e à toxicidade da molécula. Nos sistemas 
nanoemulsionados a AmB apresenta-se na forma agregada e multi-agregada. Na 
microemulsão, está incorporada na forma monomérica. Os sistemas micelares aquecidos 
  
 
dão lugar à formação de super-agregados de AmB enquanto os sistemas lipossomais são 
incapazes de se modificar em super-agregados. O derivado solúvel de AmB apresentou 
características que diferem da AmB original. Contudo, quando incorporado na 
microemulsão, o estado de agregação é similar ao da molécula original tanto nas análises 
de UV-Vis quanto de dicroísmo circular. Pode-se concluir que a forma de agregação de 
AmB varia não somente de acordo com o tipo de carreador, mas também com sua 
concentração no meio e com o tipo de incorporação, ainda que num mesmo tipo de 
carreador. Finalmente, o derivado solúvel abre a possibilidade de veiculação do fármaco 
em carreadores de caráter aquoso para o tratamento de diversas enfermidades e por várias 
vias de administração. 
  
  
 
RÉSUMÉ 
 
L'amphotéricine B (AmB) est une molécule utilisée en thérapeutique pour ses 
propriétés antifongiques remarquables.  Cependant, ses caractéristiques physico-
chimiques très particulières, puisqu’elle est à la fois amphiphile et amphotère, rendent 
difficile la conception et la fabrication de systèmes thérapeutiques chargés en AmB qui 
soient simultanément efficaces et peu toxiques. Au plan physico-chimique, les 
médicaments contenant de l’AmB et disponibles sur le marché, sont constitués de 
micelles, de liposomes ou de complexes lipidiques auxquels l’AmB est physiquement 
associée. Ces médicaments sont tous administrés par la voie parentérale. La littérature 
montre qu'il existe une relation intime entre la façon dont l’AmB est associée au système 
transporteur et les effets pharmacologiques et toxicologiques qui sont observés. Malgré 
de très nombreuses études, l’état d’association des molécules d’AmB dans les différentes 
formulations commercialisées contenant de l'AmB n’est toujours pas connus avec 
suffisamment de précision. Pour cette raison, le but de ce travail expérimental est de 
caractériser différents systèmes contenant de l'AmB, dans l’objectif de prédire les effets 
biologiques induits par l’état d’association de cette molécule à ces systèmes 
supramoléculaires. Les systèmes micellaires contenant de l'AmB ont été les premiers 
produits mis sur le marché dans les années 1960 et les brevets protégeant ces produits ont 
expiré depuis quelques années. Dans ce travail, nous avons caractérisé un système 
micellaire original ainsi que deux autres produits similaires tout en les comparant. De 
plus, nous avons étudié les mécanismes par lesquels se forment des super-agrégats 
d’AmB par l'augmentation de la stabilité des systèmes chauffés. Dans un second temps 
et pour la première fois, la capacité de l’AmBisome®, un système liposomique 
commercialement disponible d’AmB, à former des super-aggrégats a également été 
caractérisée et testée. Enfin, l'incorporation de l'AmB dans des systèmes de type nano- et 
micro-émulsion a été étudiée, ainsi que ses caractéristiques physico-chimiques lorsqu’elle 
est associée à ces systèmes, avant d’être appliquée au traitement des maladies oculaires 
fongiques et de la leishmaniose viscérale. Les principales techniques utilisées pour la 
caractérisation physico-chimiques de l’état d’agrégation ont été : (i) la spectroscopie 
électronique (UV-Vis), (ii) le dichroïsme circulaire (DC) et (iii) la diffusion dynamique 
de la lumière (DLS). La calorimétrie à titrage isotherme (ITC) a été utilisée afin de tenter 
de mesurer l’énergie de formation des super-agrégats. De plus, un dérivé soluble de 
  
 
l’AmB a été développé et caractérisé par spectroscopie de masse atomique, infrarouge, 
UV-Vis et dichroïsme circulaire (DC). Afin de disposer d’un système d’administration 
adéquat, ce dérivé soluble a été ensuite incorporé dans une micro-émulsion. Au total, 
l’ensemble des travaux expérimentaux conduits, montrent que l’état d'agrégation 
moléculaire de l’AmB dépend très largement du système d’administration utilisé, ainsi 
que des procédés par lesquels l’AmB est associées à ces systè-mes. Ces résultats ont une 
réelle importance pratique puisque la littérature montre sans ambiguïté que l'efficacité du 
médicament ainsi qu’à sa toxicité dépendent étroitement de l'état d'agrégation de l’AmB. 
Ainsi, dans la nanoémulsion, l’AmB se trouve dans des états agrégés et multi-agrégés. 
Au contraire, dans la micro-émulsion, l’AmB se présente plutôt sous forme 
« monomère ». Une fois chauffés, les systèmes micellaires forment des super-agrégats 
d'AmB, tandis que les liposomes étudiés sont incapables de donner naissance à cette 
structure supramoléculaire. Enfin, le dérivé soluble d'AmB que nous avons préparé 
présente des caractéristiques distinctes par rapport à la molécule d'origine. Cependant, 
une fois associé à une microémulsion,  son état d'agrégation est modifié et redevient 
similaire à celui de l'AmB originale, comme l’indique les études en UV-Vis et en 
dichroïsme circulaire. On peut donc conclure de ce travail que l'état d'agrégation d'AmB 
varie considérablement en fonction du type de système d’administration utilisé, de la 
concentration de l’AmB ainsi que du mode d'incorporation de la molécule, y compris 
pour un même système. Enfin, ce travail a permis la mise au point d’un dérivé soluble 
original de l’AmB qui offre la possibilité d’utiliser des formulations aqueuses adaptées à 
différentes voies d’administration et pourrait renouveler l’intérêt de cette molécule 
ancienne dans le traitement de différentes pathologies fongiques pour lesquelles il 
n’existe pas de formulations réellement adapatées. 
 
  
  
 
LIST OF FIGURES 
 
General Introduction  
Figure 1. Timeline of antibiotic discovery, modified from Silver (2011). 21 
Figure 2. Time from antibiotic approval or introduction to detection of 
resistance in clinical samples, extracted from Marston et al. 
(2016). 
23 
Figure 3. Model presenting localization, molecular organization and 
orientation of AmB with respect to a lipid membrane with and 
without molecular sterols. Extracted from Grudzinski et al. 
(2016). 
23 
Figure 4. Schemes of pore formation by AmB monomers in cholesterol-
containing membranes a) and ergosterol-containing membrane 
b). AmB aggregates forming pores in ergosterol- or cholesterol-
containing membranes. Extracted from Bratjburg and Bolard 
(1996). 
24 
Figure 5. UV-Vis spectra for monomers (M), aggregates (A) and super-
aggregates (At); B) CD spectra for monomers, aggregates and 
super-aggregates, extracted from Gaboriau et al. (1997) 
25 
 
Section I 
 
Chapter I  
Figure 1. The molecular structure of amphotericin: a) amphotericin B b) 
amphotericin A. 
35 
Figure 2. AmB electronic configuration spectra: monomers, aggregates 
and superaggregates. 
36 
Figure 3. Structural schemes of AmB-based formulations already in the 
market: a) micellar systems (Fungizone® and others) b) disk-like 
lipid complex (Amphotec®) c) ribbon-like colloidal dispersion 
(Abelcet®) d) liposomal systems (AmBisome® and others). 
39 
 
 
  
 
Section II 
Chapter II  
Figure 1. Amphotericin B molecular structure. 68 
Figure 2. UV-Vis electronic spectrum of pure AmB in methanol. 72 
Figure 3. AmB calibration curve in methanol. 73 
Figure 4. AmB calibration curve in the range of Beer-Lambert law. 73 
Figure 5. Electronic absorption spectra of samples A, B and C diluted in 
water. Labeled concentration 5x10-6 M AmB. 
74 
Figure 6. Relation between AmB species: aggregates and monomers, 
calculated from UV-Vis absorbance at 325 and 408 nm 
respectively. 
75 
Figure 7. CD spectra of AmB-containing micellar systems at 5.10-5 M 
AmB in water. Values were corrected in b) according to the 
quantified AmB. 
75 
Figure 8. CD spectra of product A in different concentrations: from 5.10-
5 to 5.10-8 M AmB 
76 
Figure 9. Size distribution for products A, B and C: a) size distribution for 
number b) size distribution for intensity. 
77 
 
Chapter III 
 
 
Figure 1. UV-Vis spectra in water for a) Anforicin® B and b) AmBisome® 
before (upper panel) and after (bottom panel) heating process, 
recorded along 28 days from the initial concentration of 5x10-6 
M AmB. 
93 
Figure 2. AmB CD spectra in water for a) liposomal and b) micellar 
preparation. Before (upper panel) and after (bottom panel) 
heating process, in three concentrations. 
94 
Figure 3. UV-Vis quantification (%) of AmB-containing micellar and 
liposomal products. Heated (discontinuous lines) and unheated 
products were analyzed. 
95 
Figure 4. Thermograms of the Anforicin B (5e-3 M) record in different 
temperatures: a) 40 ºC; b) 50 ºC; c) 60 ºC and d) 70 ºC. The 
96 
  
 
injections define the beginning and the end of the counted time 
(20 minutes). 
Figure 5. Comparison of the size of an AmB micellar solution after 
heating process at four different temperatures by naked eye 
(upper panel) and DLS (bottom panel). 
97 
Figure 6. Spectra of Anforicin® B solution (5x10-3 M AmB) heated at 
different temperatures in an ITC equipment. 
97 
Figure 7. Thermogram for the dilution of an AmB-SD solution, from 
5x10-5 to 5x10-8 M AmB. 
98 
Figure 8. CD spectra of AmB-SD solution as oligomer aggregates (5x10-
5 M) and AmB monomers (5x10-8 M). 
99 
Figure 9. Scheme of super-aggregate formation: AmB coexists as 
monomers and oligomers in solution after mild heating super-
aggregates are formed in the expenses of the previous AmB 
forms (Based on Gaboriau et al. (1997). 
101 
 
Section III 
 
Chapter IV  
Figure 1. AmB solubilization in function of NaOH 1N addition and its 
influence on the drug aggregation state. 
117 
Figure 2. AmB solubility profile in nano- and micro-emulsion. The 
percentile of drug solubility (5mg/mL max) is showed in the 
upper panel and the aggregation pattern in function of the added 
NaOH 1N, by UV-Vis, is presented in the bottom panel. 
118 
Figure 3. AmB aggregation pattern according to the drug concentration 
loaded into the nano-emulsion. 
119 
Figure 4. Change of drug aggregation pattern into nano-emulsion 
according to the pH. 
120 
Figure 5. Characterization of nano-emulsion before and after AmB 
loading. A) zeta potential B) droplet size. 
120 
Figure 6. AmB aggregation pattern into NanAmB according to the pH 121 
Figure 7. CD spectra of blank nano-emulsion (Nano) and after AmB 
loading by two incorporation methods. 
122 
  
 
Figure 8. DLS analysis of blank nano-emulsion and AmB-loaded systems 
during (NanAmB) and after (Nano + AmB) nano-emulsion 
preparation. 
122 
 
Chapter V 
 
 
Figure 1. Pseudo-ternary phase diagrams of the system containing 
Miglyol® 812N (oil phase- O), isotonic phosphate buffer pH 7.4 
(aqueous phase- W), Lipoid® S100, and Tween® 80 (surfactants- 
S), showing the area of existence of microemulsions (MEs) and 
the point chosen to produce the blank ME formulation for future 
studies. 
129 
Figure 2. Rheological behavior of the blank microemulsion (ME-2a) and 
Amphotericin B-loaded microemulsion (AmB-ME-2b). 
130 
Figure 3. TEM microphotography of the microemulsion. 130 
Figure 4. UV-Vis absorption spectra of the standard Amphotericin B 
(AmB) in methanol and the Amphotericin B-loaded 
microemulsion (AmB-ME) in microemulsion (ME) (4a). UV-
Vis absorption spectra of the micelle dosage form of 
amphotericin B (AmB-M) and the Amphotericin B-loaded 
microemulsion (AmB-ME) in phosphate buffer (pH 7.4) (4b) 
131 
Figure 5. Profile of toxicity of AmB-M and AmB-ME on RBC. (5a) Hb 
leakage, and (5b) K+ leakage. 
132 
 
Section IV 
 
Chapter VI  
Figure 1. Infra-Red spectra of AmB (blue line) and its soluble derivative 
(red line). The lost of a signal band is evidenced. 
141 
Figure 2. UV-Vis spectrum of AmB-derivative-containing microemulsion 
diluted in water. 
143 
Figure 3.  Scheme of AmB derivative aggregation in water and in 
microemulsion medium. 
144 
Figure 4. CD spectra of AmB-derivative encapsulated in microemulsion. 
Full line represents Day 0 and dotted line, Day 7. 
145 
  
 
LIST OF TABLES 
 
Section I   
Chapter I   
Table 1. List of some available AmB-based products 37 
 
Section II 
 
 
Chapter II   
Table 1. List of some AmB-based micellar systems available in the 
market. 
69 
Table 2. Quantification of the AmB content in AmB-based micellar 
systems. 
74 
 
Section III 
 
 
Chapter IV   
Table 1. List of ingredients for micro-emulsion prepare. 115 
Table 2. List of ingredients for nano-emulsion prepare. 115 
Table 3. Relation between alkaline agent volume and solution pH. 116 
Table 4. Droplet size and polydispersity index (PdI) of nano-emulsion 
loaded with different amounts of AmB. 
119 
 
Chapter V 
 
 
Table 1. Physicochemical parameters of blank microemulsion (ME) and 
amphotericin B-loaded microemulsion (AmB-ME) (Mean ± 
SD). 
130 
Table 2. Antifungal susceptibility of Amphotericin B-loaded 
microemulsion (AmB-ME) against Candida and Fusarium 
strains. 
132 
 
 
  
 
 
TABLE OF CONTENTS 
 
General Introduction……………………………………………………….... 20 
SECTION I PHARMACEUTICAL STRATEGIES FOR 
AMPHOTERICIN B DELIVERY………………………... 29 
CHAPTER I Pharmaceutical strategies for amphotericin B 
delivery……… 
31 
SECTION II AmB-CONTAINING MICELLAR SYSTEMS: 
CHARACTERIZATION OF SIMILARS AND SUPER-
AGGREGATES FORMATION………………….………... 63 
CHAPTER II Amphotericin B-containing sodium deoxycholate micellar 
systems: a comparison of physicochemical characteristics 
of marketed products …………………………………………… 65 
CHAPTER III Amphotericin B super-aggregates: formation and influence 
on the drug stability………………………………………….….. 86 
SECTION III INCORPORATION OF AMPHOTERICIN B INTO 
EMULSION SYSTEMS…………………………………... 111 
CHAPTER IV AmB loading into micro- and nano-emulsion ………………... 113 
CHAPTER V Development and characterization of a microemulsion 
system containing amphotericin B with potential ocular 
applications………………………………………………………. 125 
SECTION IV VEHICULATION OF AN AmB-SOLUBLE 
DERIVATIVE INTO A MICRO-EMULSION SYSTEM... 138 
CHAPTER VI Microemulsion encapsulation of an AmB soluble  
derivative………………………………………………………… 140 
General Discussion ........................................................................................... 147 
  
 
 
Conclusions ...................................................................................................... 160 
Synthèse de la Thèse ........................................................................................ 163 
 Enclosures 176 
 List of abstracts presented in Conferences 177 
 Stearylamine-containing cationic nanoemulsions as a 
promising carrier for gene delivery 179 
 Short Curriculum Vitae 181 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
 
 21 
 
GENERAL INTRODUCTION 
 
The emergence of the antibiotics has revolutionized the practice of medicine by 
enabling breakthroughs across the spectrum of clinical medicine (1). In this context, the 
nature has been a source of medicinal products for millennia, with many useful active 
substances obtained from plant sources and then, in the 20th century, the discovery of 
penicillin was the start pointing for drug discovery from microbial sources. 
The majority of drugs have been developed from lead structures on the basis of 
natural products synthesized by bacteria. It is estimated that during the golden era (1940 
– 1970) of microbial natural product screening, tens of millions of soil microorganisms 
have been screened, given birth to substances widely prescribed as antibacterial 
therapeutics nowadays (Figure 1) (2). 
 
Figure 1. Timeline of antibiotic discovery, modified from Silver (2011)(3). 
 
Among the antibiotics discovered during the golden era figures the amphotericin 
B (AmB), which is a polyene macrolide derived from the actinomycete Streptomyces 
nodosus. AmB was discovered in 1953, three years after the discovery of nystatin, from 
 22 
 
an isolate culture of soil obtained in the Orinoco basin, in Venezuela. Although the 
antifungal spectrum and general chemical properties were similar for both drugs, AmB 
presented several pronounced differences when compared to nystatin (4). 
After complete purification, two new antifungal substances had been revealed: 
amphotericin A and amphotericin B. The A component possessed a tetraene chromophore 
in the ultraviolet (UV), whereas the B component was a heptaene with considerably 
greater inhibitory activity than either nystatin or amphotericin A (4). 
Considering the exposed, one might wonder “why to study such an old molecule?” 
For wich we can answer with the slow speed of drug discovery, the development of drug 
resistance and the lack of information needed about AmB behavior in different situations. 
As observed in Figure 1, an antibiotic discovery void period occurred. In fact, after 
the golden era few new antibiotics have been registered by the FDA. For example, from 
the end of 2012 up today, only 5 antimicrobials have been approved by the agency (5), 
highlighting the need of a better understanding and exploitation of available antimicrobial 
agents.  
The slow rate of antibiotic discovery is due to the difficult in discovering novel 
chemicals that have selectivity and the increased regulatory scrutiny for safety and 
efficacy. Furthermore, the demonstration of superiority of the new compound is essential 
in order to rationalize pricing and to assure a return on the financial investment made (6). 
 Besides, the antimicrobial resistance is an important point that has to be taken in 
consideration. The antibiotic resistance emergence varies in time according to the drug 
class and spread use. For example, if in one hand vancomycin did not present drug 
resistance for more than three decades’ period of use, in other hand, daptomycin 
experienced it in a period of less than five years after its discovery. A relation of time 
between drug discovery and the report of clinical resistance is presented in the Figure 2. 
 It can be observed that the more recently discovered antibiotics experienced 
microorganism resistance in a short period of time (less than five years). This fact raises 
a concern about the arsenal of drugs we will have to fight against infections in the future. 
In this context, it is interesting the fact that only few cases of AmB resistance have been 
reported in humans up to now. In general, resistance to AmB is related to modification 
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on the parasite membrane sterol (7), an essential component for the drug mechanism of 
action, the pore formation that allows ions leakage and cell death. 
 
Figure 2. Time from antibiotic approval or introduction to detection of resistance in 
clinical samples, extracted from Marston et al. (2016) (1). 
The AmB mechanism of action has been recently reinforced by Grudzinski et al. 
(2016) (8), showing that the presence of sterols in the membrane lipid phase promoted 
formation of supramolecular structures of AmB and their penetration into the membrane 
hydrophobic core (Figure 3). 
 
Figure 3. Model presenting localization, molecular organization and orientation of 
AmB with respect to a lipid membrane with and without molecular sterols. Extracted 
from Grudzinski et al. (2016)(8). 
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The effect of AmB on lipid membrane has showed to be multi-modal, and among 
various molecular mechanisms associated with interaction of AmB with lipid membranes 
we can mention the destabilization of molecular order of lipids and self-assembly of the 
drug molecules within the lipid phase (8). 
AmB tends to self-associate in aqueous media due to its physicochemical features. 
This characteristic is intimately linked to the drug activity, but also with toxic effects (9). 
Thus, the importance of knowing the AmB aggregation state: drug monomers are 
supposed to bind preferable to ergosterol while aggregates tends to lose specificity, 
binding to both cholesterol and ergosterol (10, 11). Super-aggregates, in turn, are 
supposed to act as a monomer reservoir, delivering monomers to the medium (12).  
A scheme showing the importance of the aggregation state on the pore formation 
in cholesterol- and ergosterol-containing membranes is displayed in the Figure 4. 
 
Figure 4. Schemes of pore formation by AmB monomers in cholesterol-containing 
membranes a) and ergosterol-containing membrane b). AmB aggregates forming pores 
in ergosterol- or cholesterol-containing membranes. Extracted from Bratjburg and 
Bolard (1996) (13). 
 
In the proposed model, more AmB would be recruited in order to form pores in 
cholesterol-containing membranes, while in the ergosterol-containing membrane the 
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sterol makes a part given support to the pore formation. When self-associated or 
aggregated, AmB lose selectivity making pores in both sterol types.  
Concerning the sterol types, ergosterol is found in parasitic membranes such as 
the ones of fungi and some protozoa species, as Leishmania sp.. That is why AmB is 
already used as the golden standard for the treatment of deep fungal infections and 
leishmaniasis in many countries. But, on the other hand, when self-associated, the drug 
can bind to cholesterol, the sterol present in the membrane of mammalian cells, being 
responsible for the drug toxic effect. 
The AmB molecular association can be studied from spectroscopy since the 
heptaene chain composing the AmB molecule gives a good fingerprint to it on UV-Visible 
(UV-Vis) and circular dichroism (CD) (14), being sensible tools for follow up of 
molecular changes. Then, when the aggregation phenomena occurs, it readily affects 
spectra record (Figure 5). 
 
Figure 5. A) UV-Vis spectra for monomers (M), aggregates (A) and super-aggregates 
(At); B) CD spectra for monomers, aggregates and super-aggregates, extracted from 
Gaboriau et al. (1997) (15). 
 The monomeric form is presented in the graphic as “M”. Three maxima are found 
when the drug is in the form of monomers and no signal is observed by CD. When the 
drug is aggregated, one new spectra appears, blue shifted, in the expenses of monomers 
when observed by UV-Vis. “A” represents self-associated AmB and “At” the mild heated 
solution of AmB, forming drug super-aggregates. In CD analysis, AmB aggregation 
causes a bisignated spectra that is also blue shifted when super-aggregates are analyzed. 
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 Due to the AmB low water solubility, the drug has been loaded in specially 
designed pharmaceutical preparations. The first AmB-based product was a micellar 
system, launched in the 1960’s. Almost thirty years later, in the middle of the 1990’s, 
other products such as lipid complexes, colloidal dispersion and liposomes were approved 
and put on the market for clinical use (11). However, the interaction among the drug and 
its carrier influenced on the drug aggregation state, and consequently, on its biological 
activity (13). Then, this work was dedicated to the study of AmB aggregation state into 
different carrier systems, in which marketed and new systems were analyzed.  
This thesis memoire is divided in four sections. In the first section we have one 
review paper about pharmaceutical strategies for AmB delivery: this article presents the 
already marketed products as well as new approaches aiming the improvement of AmB 
safety. The second section is devoted to the micellar systems of AmB: they were the first 
product launched and still useful in therapeutics. We have analyzed similar products from 
three different countries and also the possibility of forming super-aggregates, comparing 
micellar and liposomal systems. In the third section we report the AmB incorporation into 
emulsion systems, reinforcing the potential of such preparations for ocular application 
and antileishmanial treatment. The fourth and last section, presents a patent of the 
production process of an AmB-soluble derivative and a report of the derivative 
incorporation into a microemulsion system. 
Concluding remarks closes this thesis, dedicated to the AmB. In addition, as an 
appendix, there are an article and one patent dedicated to emulsion systems intended to 
gene delivery, a contextualization is given as appendix introduction. 
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BRIEFING 
 
 Amphotericin B (AmB) is a quite old molecule, discovered in the 1950’s. 
However, the studies dealing with this molecule are still in evidence. Much has been done 
in the last 60 years: the antibiotic structure was fully described and the drug features 
clarified. The AmB mechanism of action is still in discussion, despite the evidences of 
mechanistic pore formation and membrane oxidation. 
 The drug is available in the market in a few pharmaceutical presentations and this 
fact is mainly due to the drug physicochemical features. Then, the first section of this 
thesis is composed of one chapter bringing a review manuscript discussing important 
aspects of the AmB molecule, such as its physicochemical characteristics, aggregation 
patterns, systems marketed worldwide and mainly the new pharmaceutical strategies for 
AmB delivery. 
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Abstract 
 
The amphotericin B (AmB) is an antibiotic used for the treatment of systemic fungal 
infections and leishmaniasis. The AmB molecule has amphiphilic and amphipathic 
properties, which make difficult its load into pharmaceutical carriers. Since its discovery 
in the 1950’s, just a few kind of pharmaceutical products were developed and are 
available in the market worldwide. However, these products show problems regarding 
toxicity (micelles) and high cost, besides the fact of been available only by intravenous 
administration. Then, the development of new pharmaceutical systems is mandatory. In 
this context we reviewed the strategies used for the development of new 
nanotechnological devices that could improve AmB solubility and safety. In conclusion, 
AmB is an old molecule that has not yet achieved its maximum on pharmaceutical use, 
due to the lack of specific drug carriers, even though much has been done in the scenery 
of lipid-based AmB-loaded systems, evidencing challenges and opportunities. 
 
 
 
 
 
 
 
 
Key-words: amphotericin b; micelles; colloidal systems; liposomes; microemulsion; 
nanoemulsions; cochleates; nanoparticles;  
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I. INTRODUCTION 
The amphotericin B (AmB) is an antibiotic widely used for the treatment of life-
threatening systemic fungal infections and more recently used against the protozoa 
Leishmania (1, 2). The drug presents peculiar physicochemical characteristics that make 
difficult its solubilization in aqueous solvents (3).  
Nowadays, there are in the market micelles, lipid-based and liposomal systems 
containing AmB, which are administered only intravenously. Researchers are still looking 
for systems that would be safer and/or of lower cost than the available products (4) and 
also that could be administered for other routes. 
Many approaches have been applied to the development of new AmB products. 
However, when the molecule is loaded into a carrier, new chemical interactions are built 
and  may change the AmB aggregation state, consequently modifying the activity and 
toxicity profile of the final product (5, 6). 
In this review, pharmaceutical strategies for AmB delivery are revisited beginning 
with the first micellar formulation up to recent AmB-delivery approaches. 
 
II. AMPHOTERICIN MOLECULAR CHARACTERISTICS 
The amphotericin molecule is an antibiotic extracted from the Streptomyces 
nodosus fungi, which was first isolated from a ground sample obtained on the region of 
the Orinoco River, in South America (3, 7). The amphotericin was patented in 1959  as 
the general name given for two molecules: amphotericin A (AmA) (8) and amphotericin 
B (AmB) (7). The structure of both molecules of amphotericin were elucidated and they 
are extremely similar, the only difference is a single bond between carbons 28 and 29 in 
AmA, instead of a double bond in the AmB molecule (9-11) (Figure 1). As demonstrated 
on the amphotericin’s patents (7, 8), the molecules are extracted together as a pool and 
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then purified. The amphotericin purification is an important step, once the AmA molecule 
has low antifungal activity when compared to AmB. Its concentration into the commercial 
preparation is frequently below 5% (12). 
 
Figure 1. The molecular structure of amphotericin: a) amphotericin B; b) amphotericin 
A. 
The AmB molecule (C47H73NO17) has hydrophilic (due to the presence of seven 
hydroxyl groups and an ester carbonyl group) and hydrophobic portions (due to a polyene 
group, a rigid heptaene chain) (13) (Figure 1a). Besides its amphiphilic properties, this 
molecule also shows amphoteric characteristics, due to the presence of an amine group 
(pKa 8.12) and one carboxyl group (pKa 3.72) (14). These characteristics have an 
important role on the high insolubility of the molecule in aqueous medium (6). Hence, its 
load within pharmaceutical preparations is hard to be achieved. 
Due to the amphiphilic properties of the molecule, the AmB tends to self-
aggregate in aqueous medium (15). Then, the molecule can be found as monomers, 
soluble aggregates, insoluble aggregates and also as superaggregates (Figure 2), 
depending on the medium and drug concentration. The drug aggregation state plays an 
important role on drug toxicity (16). 
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Figure 2. AmB electronic configuration spectra: monomers, aggregates and 
superaggregates. 
 
The AmB mechanism of action is controversial. It is generally believed that it 
binds to sterol of biological membranes forming trans-membrane pores that cause the 
leakage of ions and consequent disruption of the cell (3, 17). However, the drug is not 
specific for the parasite sterol (ergosterol) and can also bind to the mammalian 
cholesterol, since they are structurally quite similar (2). As aforementioned, AmB 
aggregation state seems to play an important role on the drug toxicity, it was reported that 
when it is delivered as monomers, AmB preferably binds to ergosterol, being less toxic 
for the mammalian cells (5, 18). 
 
III. MARKETED SYSTEMS 
After AmB discovery in the 1950’s, the first AmB-based product was approved 
by the Food and Drug Administration (FDA) in 1966, under the form of a micellar 
solution called Fungizone®. This presentation was for decades the only AmB product 
available worldwide. After that, in 1990’s, other products were approved by FDA and 
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launched into the market such as the Fungizone® generic, AmB-lipid complexes, and 
lately, a liposomal-based product. Once the patents of such products have expired, similar 
products have appeared worldwide (Table 1). 
 
Table 1. List of some available AmB-based products 
Product Supplier / Country FDA approval (year) 
Micellar system 
Fungizone® Bristol-Meyers Squibb/ US 1966 
Amphotericin B X-Gen Pharms/US 1992 
Anforicin® Cristália/BR  
Funtex B® Cibla/IN  
Unianf® União Química /BR  
Amphotret® Bharat Serum/IN  
Photericin B® Cipla/IN  
Amphotin-Vit® Health Biotech LTDA /IN  
Fungitericin® Lifecare Innovations/IN  
Amphotin® United biotech/IN  
Anfocam® Dabur India ltd/IN  
Hospicin B® Alkem Laboratories ltd/IN  
Amtericin® VHB lifesciences inc/IN  
Ambilip® United biotech/IN  
Amphonex® Bharat serum/IN  
Amfitas® Intas/IN  
AmB Lipid complex 
Abelcet® Sigma Tau Pharm / US 1995 
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Anolip® Samarth/IN  
Amphotin-Lip® United Biotech/IN  
Ampholip® Bharat serum/IN  
AmB Colloidal dispersion 
Amphotec® Three Rivers Pharm. /US 1996 
Amphocil® Sequus Pharmaceuticals  
Liposomal system 
AmBisome® Gilead/UK 1997 
Fungisome® Lifecare Innovations/IN  
Phosome 10® Cipla/IN  
Anfogen® Richmond Laboratorios/AR  
Lambin® Sun Pharma Laboratories/IN  
Amphotin-LS® United Biotech Pvt Ltd/IN  
Ambihope® Abbott/IN  
Amphogard® Zydus cadila/IN  
AmB naniosuspension for injection 
Amfy® Intas Pharmaceuticals ltd/IN  
Emulsion for injection 
Amphomul® Bharat Serum and Vaccines /IN  
Lozanges for oral administration 
Fungilin® Bristol-Meyers Squibb/AU  
US = United States of America; BR = Brazil; IN = India; AR = Argentina; AU = 
Australia; 
The FDA has approved some dosage forms for AmB (3% ointment; 3% cream; 
100mg/mL oral suspension; 3% topical lotion) but just the Fungizone® for injection is 
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currently available in the USA. In 1992, X-Gen Pharm approved the first generic for 
Fungizone®, marketed as “Amphotericin B® for injection”. After that, in 1995, the AmB 
lipid complex Abelcet® was approved, being followed for Amphotec® colloidal 
dispersion (1996) and the liposomal dosage form AmBisome® (1997) (19). The approval 
of these three dosage forms, together with Doxil® (an anticancer liposome), were the first 
FDA approvals to nanoengineered medicines (20). The approval of new biotechnological 
drugs has received much more attention due to their increased specificity and lower toxic 
effects. The structural schemes of FDA approved products are depicted on Figure 3. 
 
Figure 3. Structural schemes of AmB-based formulations already in the market: a) 
micellar systems (Fungizone® and others); b) disk-like lipid complex (Amphotec®); c) 
ribbon-like colloidal dispersion (Abelcet®); d) liposomal systems (AmBisome® and 
others). Based on (5, 6). 
 
Most of AmB-based products listed on the Table 1 are micellar systems, probably 
due to the easier production when compared to the other known systems. Another 
interesting data is that most of the products listed (~70%) are produced in India. Indeed, 
a) 
b) 
c) 
d) 
Surfactant (SD) 
Phospholipids (HSPC/DSPG) 
Lipids (DMPC/DMPG) 
Cholesteryl Sulfate 
AmB 
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this fact is understandable once this country presents endemic leishmania infection areas 
where patients are refractory to the treatment with antimonials (first line treatment) (21). 
Some efforts have been made in India since 2005 in order to fight against leishmaniasis 
and a great number of clinical trials using AmB probably gave birth to new AmB-
containing products (22). 
All the systems listed in the Table 1 are intended for intravenous administration, 
except Fungilin® lozanges, In fact the advances in the engineer of drug carriers allowed 
the development of new AmB-based products, however their ability to cross the intestinal 
barrier has not yet been achieved. Fungilin® lozanges are indicated for oral delivery but 
with a topic pharmacological effect on the treatment of oral and intestinal candidiais. 
In the following lines it will be presented the AmB-based products already 
approved by the FDA that are/were available in the market. 
Fungizone® 
The Fungizone® was launched in the 1960’s consisting of a mix of 50 mg of AmB 
and 41 mg of sodium deoxycholate (SD) (4, 5, 17) constituting for a long period of time 
the only AmB-based product available in the market. Side effects such as headache, fever, 
chills, nausea and mainly nephrotoxicity have been related to its infusion (2, 17, 23-26). 
However, due to its low cost and high antifungal efficacy, it is broadly used nowadays. 
To avoid the Fungizone’s drawbacks and to increase its therapeutic index some 
strategies have been applied. The AmB aggregation state has an important role on the 
host toxicity (18),  when the AmB-SD is dissolved in water, the drug molecules are mainly 
in the aggregated form (16, 27, 28) that is supposed to bind the cholesterol of host cells, 
causing toxic effects. One strategy for increasing AmB-SD therapeutic index could be the 
delivery of AmB monomers. In fact, it was demonstrated that AmB-SD has its deleterious 
effects balanced by the presence of serum albumin, which influences the AmB 
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aggregation state towards monomers (29). In this way, other strategies have been 
published such as the use of other micellar (30) or lipid systems (4, 31, 32) to dilute 
Fungizone® as well as the mild heating of the product, in order to form AmB 
superaggregates (25, 26, 28, 33). 
Abelcet®  
The product is an AmB lipid complex (AmBLC) consisting of a 1:1 molar ratio 
of drug to lipids. The lipids herein used are dimyristoyl phosphatidylcholine (DMPC) and 
dimyristoyl phosphatidylglycerol (DMPG) (7:3 molar ratio) (5, 6, 34-38). 
The formation of the system is possible dependent of an AmB concentration 
higher than 3 mol% (34, 38).  Into this system, the drug is complexed with a ribbon-like 
non-liposomal structure forming lipid-stabilized AmB aggregates. It is suggested that the 
new structure is responsible for the drug toxicity attenuation (36). In fact, a low 
concentration of monomers on the medium is enough to kill the fungal cell but insufficient 
to cause toxicity to mammalian (34). Indeed, phospholipases are required to hydrolizate 
the lipids in order to allow the drug release (35). 
Due to Abelcet® low toxicity, it is possible to increase the quantity of drug 
administered to the patient. In this way, better fungicidal level is achieved. Besides, even 
in higher concentration, this formulation is better tolerated than AmB-SD (39). Moreover, 
it is effective against fungal infections on bone marrow transplanted patients who had 
failed to respond to previous antifungal therapy (even treated with AmB) (40). 
 
 
Amphotec®  
The Amphotec®, an AmB colloidal dispersion (ABCD) was the third FDA 
approved AmB based product (34), it is presented as uniform disk shaped particles of 
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around 115 nm where the drug is complexed with cholesteryl sulphate in a 1:1 proportion 
(41-43). ABCDs were marketed as Amphotec® (USA) and Amphocil® (Europe) (6, 17). 
The disc-resemble particles of this system have similar antifungal activity and 
decreased toxicity when compared to Fungizone®. Such an improvement in safety is due 
to the strong interaction of the drug with cholesteryl sulfate, reducing the amount of free 
AmB available in the blood (6, 42). However, ABCD showed up regulation of 
inflammatory genes and consequently, similar or even more infusion-related reaction 
compared to AmB-SD. It is probably why its production was discontinued in 2011 (17). 
AmBisome®  
The AmBisome® is a single bilayer liposome that was introduced in the European 
market in 1989 and approved by the FDA for the treatment of leishmaniasis in 1997 (6). 
The product consists of AmB, hydrogenated soya phosphatidylcholine (HSPC), 
cholesterol, distearoyl phosphatidylglycerol (DSPG) and sucrose, where the AmB 
molecule is intercalated within the liposomal bilayer (5, 17). 
The low toxicity of liposomal systems is due to their small size which makes 
possible their prolonged circulation in the blood, as well as due to their composition: once 
cholesterol is a component of the system, AmB binds to it and remains attached until it 
binds to an ergosterol-containing membrane. There is also a negative charged component 
in the system (DSPG) that complex the positive AmB amine group (6, 44, 45). 
Consequently, less free AmB is found in the medium interacting with mammalian cells 
and causing side effects (17, 46). 
The AmB encapsulation into liposomes could protect the drug against degradation 
processes such as chemical inactivation, enzymatic degradation and immunological 
neutralization (47). Indeed, it was demonstrated that liposomal-based eye drops were 
stable for up to six months after reconstitution (48). 
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AmBisome® has its high cost (when compared to other marketed systems) 
justified by the advantages in terms of high bioavailabitity and few side-effects (6). There 
are already some AmBisome® similars on the market. However, studies showed that some 
of these products do not have equivalence with AmBisome® regarding safety or efficacy 
(44, 49).  Indeed, even products having the same composition presented different results 
concerning antifungal activity and toxicity both in vitro and in vivo. It is suggested that 
the manufacture process could play an important role on the differences between products 
(47, 50). 
So far, many studies have been performed comparing the effectiveness of AmB-
loaded marketed products. As a common consensus, AmB-based micelle is the most toxic 
system despite its high efficiency. The new lipid-based formulations are safer and well 
tolerated even for immunocompromised and HIV co-infected patients, but they are cost-
limiting mainly for people in developing countries (17, 51, 52). That is the reason why 
pharmaceutical strategies for AmB delivery are still under development. 
 
IV. NEW STRATEGIES FOR AMB DELIVERY (NOT MARKETED) 
The strategies described above are not completely new. In fact, the majority of 
researchers deal with the nanotechnology in order to produce nanodevices well known 
such as micelles, nanoparticles, microemulsions, nanosuspension among other systems. 
However, the use of some components or even the methodology applied in the production 
process may turn the drug more soluble and the product more effective or less toxic. 
IV.A. Micellar Systems 
The most used strategy is the one applied to the first AmB-based product, 
micelization. It is well established that micelles are able to improve the solubility of many 
drugs and that the location of the drug depends on its hydrophobicity (53). Besides, the 
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micelle dynamics (surfactant unimers exchanges) could be responsible for the release of 
the AmB from the system (54). 
The problem behind the use of AmB-loaded micellar systems is the aggregation 
state of the drug. The AmB de-aggregation in Fungizone® was achieved by using a new 
micellar system composed of poly (ethylene glycol) distearoyl phosphatidylethanolamine 
(PEG-DSPE), a mixture that makes possible the delivery of the drug as monomers. The 
antifungal efficacy of this new system did not change and the hemolytic activity was 
lower than that of the original product (30). In the same way, but using pure AmB instead 
of AmB-SD, self-assembled PEG-block-poly(ε-caprolactone-co-trimethylenecarbonate) 
(PEG-p(CL-co-TMC)) system was able to solubilize AmB and to de-aggregate it. The 
AmB solubility in a 20% PEG-p(CL-co-TMC) micellar solution was increased more than 
100 times when compared to the drug solubility in water. AmB was found as monomers 
in the micelles and this fact was reflected on the reduction of the hemolytic drug induced 
effect. However, the antifungal effectiveness of the system was reduced (55). A similar 
behavior was observed when a gemini surfactant derived from cysteine was used for AmB 
solubilization (56). 
Another strategy developed to increase the therapeutic index of AmB-SD was 
introduced with the concept of the AmB super-aggregates. These super-aggregates 
consist of the same AmB-SD mixture of components, therefore this dispersion passes 
through a heat treatment (70 ºC for 20 minutes) that changes the supramolecular 
organization of the micellar system (27). The new structure has been reported as less toxic 
maintaining the drug activity, when compared to the un-heated AmB-SD (25, 26, 28, 33, 
57). Recently, our group have demonstrated how micelles can be re-arranged to obtain 
the super-aggregated structure after a heat process (26). Additionally, this re-builted 
 45 
 
system can be freeze-dried and maintain its physicochemical and biological properties 
(33). 
The surfactant used in the Fungizone® preparation, SD, is a bile-acid detergent. 
Other micellar systems were already prepared with SD-like components sodium cholate, 
sodium deoxycholate sulfate (SDS) and potassium deoxycholate. These micelles were 
tested for membrane permeation and they were able to increase this parameter two to five 
folds when compared to pure AmB. Among these systems, the AmB-SDS was the less 
toxic and the one who showed best permeability (58). The use of AmB-SDS showed to 
be an interesting approach for the AmB pulmonary delivery, as an aerosol dosage form, 
effective against C. albicans and C. neoformans (24). 
The use of polymers to built micelles has been well studied for AmB delivery. 
Modified alginate micelles were able to improve AmB water solubility up to 160 times, 
and to control the druamg release (90% AmB release within 14 hours) (59). Using poly- 
(dimethylmalic acid), AmB water solubility was increased 1000 times (60). 
For copolymers-based systems, the composition (ratio) of the blocks influences 
both the self-assemble and the drug incorporation. Due to it, for a system based on poly 
(isoprene-b-ethyleneoxide) copolymers, the final product did not present good 
polydispersity compromising AmB loading efficiency, droplet size and drug release (61). 
This highlights the importance of controlling the molecular weight of copolymers. For 
PDMAEMA-b-PCL-bPDMAEMA triblock copolymers, the micelles built from low 
molecular weight polymers encapsulated more AmB than those produced with polymers 
of high molecular weight. The consequence of high drug load was molecular aggregation. 
Nanocontainers prepared with high molecular weight copolymers incorporated less drug, 
presented as monomers into the system that had small droplet size and low hemotoxicity, 
without loss of effectiveness (54). A study conducted with δ-decalacton homopolymers 
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and copolymers revealed slow release and long degradation time of the drug when loaded 
in its micelles (62). It gives rise to the possibility of the use of polymeric micelles as a 
kind of depot AmB-based system. 
Cyclodextrin (CD) could be used to improve AmB solubilization and further 
micelle preparation. The use of CD for the solubilization of AmB in poloxamer micelles 
was described (63) as well as the use of hydroxypropyl-γ-CD for the treatment of 
pulmonary aspergilosis (64). Indeed, when the drug is included in a CD, only the polyene 
macrolide ring fits the CD cavity (65). Then, the arrangement of the cyclic 
polysaccharides as monomer, dimer or hybrid cyclodextrins, influences the AmB binding 
power (66). 
As it could be seem, the use of micelles are very often intended for AmB 
solubilization. New approaches such as the use of polymers on micelles formation have 
raised the possibilities of the use of this kind of systems not only for AmB solubilization 
but also for drug controlled release, consequently decreasing its toxicity. 
IV.B. Emulsion systems 
Emulsion systems are composed by two immiscible liquids dispersed within each 
other and stabilized for a surfactant film (67). These kind of systems are of easy 
preparation and can be classified as thermodynamically stable (microemulsions) or 
unstable (true emulsions and nanoemulsions) systems (68). Both of them were already 
used as AmB carriers, and the drug is supposed to be located on the droplet surface or 
liquid interfaces (14). 
Some techniques such as spontaneous emulsification, microfluidization, high 
pressure homogenization and sonication were already employed for the development of 
AmB-containing emulsion systems (69-72). Even the use of the already prepared 
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emulsion Lipofundin® have been related in the literature as an strategy for AmB 
therapeutic index improvement (4, 31, 32). 
Some studies have showed high AmB loading efficiency (> 90%) into emulsion 
systems (73-75). Indeed, AmB had its solubility improved 1000 times in a microemulsion 
system (71) and different load charges have been related, depending on the components 
used. When Captex® 200 was used as oil core 6.8mg/mL (76) and 5.0 mg/mL (23) AmB 
were loaded. For Miglyol® core, 3.0 mg/mL (72) and for cholesterol core, 2.5 mg/mL 
(77). However, there is evidence that the AmB solubilization is due to the formulation 
microstructure and not to the components themselves (78). 
When loaded into the system, the AmB molecules are mainly in the monomeric 
form (23, 70-73)  specially in microemulsion formulations. It was also found in the 
literature a case in which the drug was complexed within the emulsion droplet, but 
released as monomers (79) in a safe and efficient manner (80). 
In fact, the aggregation state of the drug was closely related to the formulation 
safety profile. Emulsions in which the drug was mainly in the monomeric state presented 
less side effects in vivo (73) and was 10-fold less toxic than AmB-SD (23). The presence 
of self-aggregates in the formulation could be responsible for its time-dependent 
cytotoxicity (71). 
These systems were already intended for different administration routes such as 
topical (75, 81), ocular (72), oral (71, 73, 74) and parenteral (4, 31, 32). For the treatment 
of different diseases, mainly fungal-caused diseases (4, 31, 32, 72, 81), but also cutaneous 
(75) and visceral leishmaniasis (73, 74). 
Special attention should be paid for formulations intended for oral and topical 
delivery. In the first case, the system must be stable in gastric and intestinal simulated 
media, promote the absorption of the drug and be well distributed to the target organ (74). 
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In the second case, it could be interesting the use of a permeability enhancer such as the 
transcutol-P (81). A formulation lacking such component failed to bypass the skin (75). 
IV.C. Liposomal systems 
Liposomes are vesicles made out of the same material as a cell membrane. It could 
be multilamellar or unilamellar and the drug may be entrapped into the aqueous and/or in 
the lipid phase (82). The launch of AmBisome®, in 90’s, improved the safety use of the 
AmB. Researchers are now using liposomes seeking other administration routes such as 
topical (83, 84), vaginal (85), oral (86) and pulmonary (87). 
Comparing liposome components, the most common ingredient is cholesterol (83, 
85, 86). Other components, like phospholipids, change in type and concentration among 
formulations. Indeed, the use of cholesterol is a strategy to maintain the drug loaded into 
the liposome.  
Even the use of Fungizone® for liposome preparation is related in the literature 
(83). In this case, liposomes were prepared with HSPD/cholesterol/stearylamine (7:2:1 
molar ratio) intended for the topical application of AmB. The liposomes were of high 
stability and deep penetration into the skin. The use of charged liposomes was also a 
strategy for the production of a vaginal intended delivery product (85). For this purpose, 
1,2 dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-3 trimethylammonium-
propane, and cholesterol (4:5:1 molar ratio) were used for liposome prepare and then 
incorporated in a thermosensitive gel of Poloxamer® 407 and Poloxamer® 188, gelling at 
37 ºC. 
The use of a plant sterol (stigmasterol) was the strategy of Iman et al. (2011) (88) 
to produce liposomes, mixing it with the new lipid 1,2-Distigmasterylhemisuccinoyl-sn-
glycero-3-phosphocholine. The system was characterized and compared with 
AmBisome®, showing similar activity against fungal and leishmania infections. The use 
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of vegetal ceramides was described by Skiba-Lahiani et al. (2015) (86), who developed 
liposomes intended for AmB oral delivery. Ceramides were important to give liposome 
membrane stability in the digestive medium. However, cholesterol and phospholipids 
were required to prevent drug leakage and to provide liposomal lamellar structure. 
A modification of the liposome preparation method was already suggested. In this 
case, proliposomes were employed (87, 89). The concentrated proliposomes were used to 
prepare unilamellar liposomes in situ, resulting in high entrapment efficiency (> 95%) 
and AmBisome® comparable release and efficacy (89). Also a chitosan-coated 
formulation intended for nebulisation was prepared by this method, showing to be active 
against C. albicans and C. tropicalis, comparable to Fungizone® (87). 
The most different liposome produced used ethanol in its composition (30-45%) 
and was called ethosome (84). It was intended for the treatment of cutaneous fungal 
infection, once the etholic nature of this carrier is supposed to enhance skin permeation. 
Besides, the AmB-loaded ethosome was mixed with Carbopol® gel, in order to prepare a 
final nanoethosome gel that could be retained for more time in the skin. The size of the 
carrier was in the range of 180 – 300 nm, showing up to 89% AmB loading efficiency. 
The drug was controlled released from the system (87% in 24 hours), although 95% of 
the free drug was released to the medium within 2 hours. When compared with marketed 
AmB by topical delivery, the new system was able to enhance drug permeation as well 
as drug deposition and improve activity against C. albicans. 
IV.D. Nanoparticles 
Nanoparticles are very versatile systems due to the possibility of easy modulation 
of important characteristics such as size, shape and surface charge, and are of particular 
interest for the encapsulation of insoluble drugs such as AmB. It is suggested that this 
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sort of carrier could improve drug solubility and increase its distribution in biological 
tissues (90). 
Many polymers and copolymers such as N-Palmitoyl-N-monomethyl-N,N-
dimethyl-N,N,N-trimethyl-6-O-glycol chitosan (GCPQ)(91), poly(ε-caprolactone) 
/poly(N,Ndimethylamino-2-ethyl methacrylate)(92), poly(lactide)-poly(ethylene glycol) 
(PLA-PEG) (93), poly(D,L-lactide-co-glycolide) (PLGA) - D-α-tocopheryl polyethylene 
glycol 1000 succinate(94), PLGA-PEG (90, 95), PLGA-b-poly(L-histidine)-b-PEG (96), 
bovine serum albumin (BSA) (97) and hydroxypropylmethylcellulose (98) have already 
been used for the production of AmB-containing nanoparticles. Besides, AmB-containing 
magnetic nanoparticles were also developed for the treatment of pulmonary infections 
(99, 100). 
In general, the drug is loaded into the nanoparticle matrix (92) and, as 
aforementioned for polymeric micelles (54), according to the polymer molecular weight 
more or less AmB can be loaded into the nanoparticle matrix. As a consequence of the 
high AmB incorporation amount, the drug is self-aggregated into the system (92, 93). 
However, the drug could also be loaded on the nanoparticle surface (99, 100) and be 
found as monomers (97, 101) depending on the nanoparticle type and polymer used. The 
nanoparticle drug load varies, the herein reviewed articles loaded > 68% AmB (90, 92-
98). However, strategies using cluster dextrin (101) and solid lipid nanoparticles built 
with theobroma oil/bees wax (102) did not present high drug load. 
The nanoparticle structure permits the decoration of its surface. Tang et al. (2015) 
(96) did it with anti-Candida albicans antibody. Besides the particle decoration, the 
polymer used by them was pH responsive, which is a very interesting approach when it 
is considered that during a fungal infection the local pH is diminished, lowering the AmB 
activity. A modification of a chitosan-based nanoparticle with a ligand 4-sulfated N-
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acetyl galactosamine (4-SO4GalNAc) is also related in the literature for the treatment of 
leishmania infected macrophages (103). These strategies lie on the drug targeting. If 
achieved, the dose may be diminished causing side effects decrease while activity is 
maintained. 
In fact, most of the nanoparticle systems were able to increase efficacy and 
decrease the toxicity when compared to free-AmB (92, 94, 96, 99) and AmB-SD (93), or, 
at least, maintain the drug efficacy while decreasing drug toxicity (96, 97, 101). Such 
results could be explained by the sustained release of the drug from the system (93, 96, 
98) that could be intended for alternative administration routes such as pulmonary (98-
100) and oral delivery (91, 95, 102). 
IV.E. Other colloidal systems 
Other colloidal systems have been studied in order to improve AmB solubilization 
and target delivery. Nanodisks produced from phospholipids and amphipathic 
apolipoproteins (104) and calcium sulfate and hydroxyapatite (105) have been described, 
opening the possibility for the treatment of diseases such as fungal osteolyelitis (105), 
that is not covered by using the marketed systems. 
Carbon nanotubes could also be used for AmB delivery (106). Pruthi et al. (2012) 
(107) loaded carbon nanotubes with AmB (which was physically adsorbed on the external 
sidewalls of the nanostructure) called AmBitubes. This system was able to load up to 75% 
AmB and sustain the drug deliver in a pH dependent manner. The system was 3 times 
less hemotoxic than the free AmB solution and had improved drug uptake by 
macrophages, resulting in an interesting strategy for AmB delivery in leishmaniasis. 
Some natural products such as bixin have demonstrated ability to disperse AmB 
in aqueous medium (108). This compound is antibacterial itself, and more effective than 
AmB-SD against C. albicans (109). 
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The use of new colloidal systems as nanogels (110) and cochleates (111) opens 
the possibility of AmB delivery by two important routes: topical and oral, respectively. 
The nanogel developed by Qasim et al. (2014) (110) was based on poly(N-
isopropylacrylamide), achieving globule sizes of around 430 nm from where the drug was 
well solubilized, controlled released and efficient against C. albicans.  
The cochleates are nano or sub-micron sized multi-lamellar cylindrical structures 
spontaneously generated by the fusion of negatively charged liposomes with metal 
cations (6, 111-115) that where already used for the oral treatment of systemic candidiasis 
(111). Results showed the system as efficient as AmB-SD by intraperitoneal injection. 
When AmB-containing cochleates were tested for the treatment of leishmania, they were 
also effective as AmB-SD with the advantage of being non-toxic for macrophages (114). 
 
V. CONCLUDING REMARKS 
 Despite all drawbacks concerning AmB physicochemical properties and adverse 
effects, scientists have been successful in creating dosage forms for this drug. Nowadays, 
there are available in the market systems based on micelles, lipids and liposomes. The 
studies comparing these products usually show the micellar system as the most effective 
one. However, using the other systems it is possible to safely increase the drug posology 
(116). 
 The main concern for the AmB lipid-based systems is the cost. Then, the majority 
of the researchers try to develop systems with properties that overcome AmB-SD 
concerning safety. 
 From the last 5 years, researches have been focused mainly on the development 
of polymeric micelles and nanoparticles. In the first case, researchers try to have the drug 
loaded as monomers once this presentation is supposed to be less toxic than AmB 
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aggregates, binding preferably to ergosterol-containing membranes. In the second case, 
as the drug is mainly entrapped into the particle matrix, the drug could be aggregated and 
the strategy lies on the AmB controlled release. Again, the aim is to release AmB 
monomers, that are less toxic and more effective against parasites and fungi. 
 Besides the improvement on the AmB therapeutic index, led by the development 
of new AmB delivery systems, many attempts are still being made on the development of 
carriers to turn possible the administration of AmB by other routes, such as oral and 
topical. So far, good results have been demonstrated by the use of cochleates and 
emulsion systems. 
 The research for the “ideal carrier” continues. The society still waits for the AmB-
containing system able to treat infections without damaging kidneys, that would treat 
diseases not only by intravenous, but by other routes and mainly, that would be affordable 
by the most needed patients. 
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BRIEFING 
 
 Micelles are known for their ability of solubilizing many water insoluble 
molecules. Not surprisingly, this was the first successful strategy for amphotericin B 
(AmB) solubilization. 
 In the 1960’s a mix of sodium deoxycholate and AmB was launched in the market 
and after 50 years, in spite of the side-effects of this medicine, it is still used in the 
therapeutics. 
 The second section of this thesis is dedicated to the AmB micellar systems, 
bringing 2 chapters in which are presented and discussed issues such as the characteristics 
of similar products and the formation of AmB super-aggregates. 
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Abstract 
 
The amphotericin B (AmB) is an antibiotic used to treat deep life-threatening fungal 
infections and also some protozoa-caused diseases such as leishmaniasis. The AmB 
physico-chemical characteristics turn difficult the drug loading into pharmaceutical 
carriers. Despite this fact, since the 1960’s, the drug has been commercialized as a mix 
of AmB and Sodium Deoxycholate (SD). Many side-effects are attributed to this system. 
However, after Fungizone’s patent expiration, similar products emerged on the market 
worldwide. The aim of this work was to compare the characteristics of three AmB-
containing SD micellar systems. Drug label, carrier size and AmB aggregation state were 
evaluated. The products presented size of around 30 nm. However, the drug label differed 
between them and according to it, systems have different aggregation state. Besides of 
evidencing the impossibility of product interchange, the findings of drug aggregation 
pattern may suggest product efficacy and safety. 
 
 
 
 
 
 
 
 
 
 
 
Key-words: Amphotericin B; UV-Vis; Circular Dicrhoism; Aggregation State;  
Introduction 
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The amphotericin B (AmB) is a polyene antibiotic extensively used to treat life-
threatening systemic fungal diseases (1, 2). The mechanism of action of the drug is not 
completely clear, it is believed that the clinic effect results from the interaction of the drug 
with the sterols of the cellular membrane, mainly the ergosterol of fungal cells. The drug 
forms pores in the cell membrane increasing its permeability and causing cell death (3, 
4). 
The molecule was discovered in the 1950’s (5) and had its structure elucidated in 
the 1970’s (6). Its structure is composed by a rectangular ring containing a 
transconjugated heptane chromophore justaposed by an acyl chain linked with many 
hydroxyls (Figure 1) (3, 7).  
 
Figure 1. Amphotericin B molecular structure. 
 
Besides of being amphiphilic, AmB is also amphoteric, once it is a zwitterionic 
molecule in solution at neutral pH: the carboxylic acid group is deprotonated while the 
amino acid group is protonated (4). Because of that, the molecule is soluble just in few 
organic solvents and insoluble in water (3). This fact turns difficult the drug loading into 
pharmaceutical carriers. 
In early 1960’s, it was developed a micellar system in which sodium deoxycholate 
(SD) solution was able to solubilize the drug. This system was patented as Fungizone® 
and is broadly used as “gold standard” to treat life-threatening fungal infections up to now 
(8-10). 
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 Fungizone® was the only AmB-based product approved by the Food and Drug 
Administration Agency (FDA) up to 1990’s. In the last 20 years it appeared in the market 
lipid-based products such as Abelcet®, Amphotec® and AmBisome® that improved AmB 
therapeutic index, since many reactions such as vomiting, headache, chills, fever and hard 
nephrotoxicity, linked to Fungizone’s infusion (8, 10, 11) were overcome by these 
products. However, those systems have much more technology involved in its preparation 
and are cost-limiting mainly for developing countries. 
  After Fungizone’s patent expiration some similar products were launched in the 
market worldwide (Table 1). Mainly in India, a developing country of pungent 
pharmaceutical industry, where the use of AmB has augmented with the increase of the 
leishmaniasis refractory treatment with antimonials (12, 13).  
Table 1. List of some AmB-based micellar systems available in the market. 
 
Product Supplier Country 
Fungizone® Bristol-Meyers Squibb USA 
Amphotericin B® X-Gen Pharms USA 
Unianf® União Química  Brazil 
Anforicin® Cristália Brazil 
Funtex B® Cibla India 
Amphotret® Bharat Serum India 
Photericin B® Cipla India 
Amphotin-Vit® Health Biotech India 
Fungitericin® Lifecare Innovations India 
Amphotin® United Biotech India 
Anfocam® Dabur India India 
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Hospicin B® Alkem Laboratories India 
Amtericin® VHB Lifesciences India 
Ambilip® United Biotech India 
Amphonex® Bharat serum India 
Amfitas® Intas India 
 
 The emergence of such a number of similar products could be relate to the ease of 
prepare of the micellar system. However it raises the doubt about the safe of the use and 
interchangeability between these systems. It is important to highlight that they are not 
generic, but similars. 
 The aim of this work was to compares the physicochemical characteristics of 
AmB-based micellar systems. For its purpose, three products were analyzed for AmB 
content, system size and degree of AmB aggregation, by UV-Vis and circular dichroism 
(CD). 
 
Methodology 
Materials 
Amphotericin B (99% purity) was purchased from Indofine Chemical Company 
(USA). The micellar systems were: Fungizone® from Bristol-Myers Squibb (France), 
Amphotret® from Bharat Serums (India) and Anforicin® B, from Cristália (Brazil). 
Methanol was HPLC grade from Merck® (France) and the ultrapure water was obtained 
by Milli® Q purification system. 
Calibration curve 
An AmB stock solution (1x10-4 M) was prepared by diluting 1.71mg AmB in 17.1 
mL methanol. In order to completely dissolve the drug, the container was put in a ultra-
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sound bath during 5 minutes. Then, the stock solution was diluted in methanol for nine 
points of AmB concentration (1.6x10-5; 8.0x10-6; 6.0x10-6; 5.0x10-6; 4.0x10-6; 2.5x10-6; 
2.0x10-6; 1.0x10-6 and 5.0x10-7 M) that were read in a Perkin Elmer (France) 
spectrophotometer with a 1cm length quartz cell. A screening was performed from 300 
to 450 nm wavelength and λmax= 405 nm were used for AmB quantification. 
AmB-SD solution preparation 
All the products: Fungizone®, Amphotret® and Anforicin® B are presented as 
lyophilized yellow powder containing 50 mg AmB and 41 mg SD. They were diluted in 
10 mL water for injection, as recommended for the suppliers and reserved for further use. 
The resulting solution was 5x10-3 M AmB concentrated. The formulations were identified 
in this study as A; B and C, randomly, to avoid commercial appeal. 
AmB quantification 
The calibration curve was used to quantify the AmB-content into the products. 
After water suspension (5x10-3 M), the products were diluted 1000-fold in methanol, in 
order to result a 5x10-6 M AmB concentration, well fitting the calibration curve and 
assuring accurate drug quantification at λmax= 405 nm. 
Evaluation of AmB aggregation state 
The systems were diluted in ultra-pure water in order to have its aggregation state 
evaluated. The drug conformation was analyzed for both electronic and circular dichroic 
(CD) spectroscopy. 
 UV-Vis spectra were recorded in a PerkinElmer (France) spectrophotometer after 
1000x dilution of the re-suspended product, using a 1cm length quartz cell. The wavescan 
was from λ = 300 to 450 nm (14). 
For circular dicrhoism (CD), transitions of AmB were recorded from dilutions of 
5x10-8 up to 5x10-5 M on a Jasco J-810 dichrograph (France), by using 10, 5, 1 and 0.1 
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cm path length quartz cells respectively. Wavescans from λ = 300 to 450 nm were carried 
out with the main objective of observing the presence of a doublet that identifies the 
presence of AmB aggregates in the medium. 
Size measurement 
The globular size was measured using a Malvern Zetasizer Nano-ZS (France) by 
dynamic light scattering (DLS) at 173° angle, 25 ºC. The powder was reconstituted in 
water and the system had its size measured. Results were reported as size distribution by 
intensity and number. 
 
Results 
Calibration curve 
The AmB molecule in a monomeric conformation absorbs at 363, 382 and 405 
nm in methanol (Figure 2). 
 
Figure 2. UV-Vis electronic spectrum of pure AmB in methanol. 
A calibration curve was built using an UV-Vis spectrophotometer and showed to 
be linear (R² = 0,9996) (Figure 3). 
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Figure 3. AmB calibration curve in methanol. 
 Eight from nine concentration points were used in the curve once the 
concentration 1.6x10-5 M gave 2.16 A.U. absorbance, very out of the Beer-Lambert 
theoretical principles. Indeed, considering the absorbance range 0.2 to 0.8, only the 
concentrations from 1.0x10-6 to 5.0x10-6 M AmB would be considered and the correlation 
coefficient R² would be 0.9999 (Figure 4). 
 
Figure 4. AmB calibration curve in the range of Beer-Lambert law. 
 The dilution for 5.0x10-6 M AmB was that chosen for further sample 
quantification. 
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AmB quantification 
The AmB quantification was performed applying the equation from the calibration 
curve aforementioned. The micellar products were suspended in water and then, 1000-
times diluted in methanol. From the wavescan 300 – 450 nm, the value of the main peak 
λmax = 405 nm was considered for AmB quantification (Table 2). 
Table 2. Quantification of the AmB content in AmB-based micellar systems. 
 
Product Abs [AmB] M 
A 1.1017 6.65 ± 0.09 
B 1.039 6.28 ± 0.18 
C 0.8197 4.97 ± 0.11 
 
AmB aggregation state 
The AmB absorption spectra were recorded by UV-Vis for all the samples after 
1000x ultrapure water dilution from the 5mg/mL reconstituted product and are depicted 
on the Figure 5. 
 
Figure 5. Electronic absorption spectra of samples A, B and C diluted in water. Labeled 
concentration 5x10-6 M AmB. 
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 The spectra were characterized for the presence of both monomers and aggregates. 
The aggregation level in the samples was then calculated as the ratio between the 
absorption of aggregates (λ = 325nm) by the absorption value of the main peak of 
monomers (λ = 408nm) (Figure 6). 
 
Figure 6. Relation between AmB species: aggregates and monomers, calculated from 
UV-Vis absorbances at 325 and 408 nm respectively. 
 The aggregation state of the samples was also evaluated by CD. All of them 
presented an exciton couplet characteristic of aggregated AmB forms (Figure 7). 
Figure 7. CD spectra of AmB-containing micellar systems at 5.10-5 M AmB in water. 
Values were corrected in b) according to the quantified AmB. 
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The CD spectra were also recorded for different AmB concentrations. All the 
samples presented same aggregation behavior while being diluted (result not shown). The 
dilution of the product A is showed on the Figure 8. 
  
Figure 8. CD spectra of product A in different concentrations: from 5.10-5 to 5.10-8 M 
AmB. 
 The ratio among the positive and negative couplet peaks were 2.0, 1.9 and 1.9 for 
the dilutions from 5.0x10-5 to 5.0x10-7 M AmB, respectively. The spectra recorded at 
5.0x10-8 M AmB did not present excitonic couplet. 
Size distribution 
 The globular size of the products were measured by DLS and reported as size 
distribution by number and intensity (Figure 9).  
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Figure 9. Size distribution for products A, B and C: a) size distribution for number; b) 
size distribution for intensity. 
In the first distribution (Figure 9a) all the products presented the same range of 
size by number, the micelles were under 100 nm size (~30 nm). By intensity (Figure 9b), 
the distribution showed to be bimodal with peaks from 20 – 40 nm and from 150 – 300 
nm. 
 
Discussion 
The optical properties of AmB, due to the presence of a system of seven 
conjugated double bonds (Figure 1), make the spectroscopic methods particularly 
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appealing for the drug study (15, 16). Indeed, polyene antibiotics absorb light between 
300 and 450 nm (7, 17). 
In this work we have prepared stock solutions of AmB in methanol, for drug 
quantification. Solvents classified as stronger or weaker proton acceptor are able to 
display AmB as monomers (7). In fact, when AmB is dissolved in organic solvents such 
methanol or in dimethyl sulfoxide at concentrations lower than 10-4 M, the drug is totally 
presented in the monomeric form (14, 18) and behaves as a normal solute in its adherence 
to Beer’s law (7). Results are in agreement with the literature, once the AmB spectra in 
methanol presented characteristic bands (362, 382 and 405 nm) related for the monomeric 
form of the drug (Figure 2) and the absorption on the main band (λmax= 405 nm) permitted 
the construction of a standard curve (Figure 3) which presented good linearity (R² = 
0,9996), permitting drug quantification in methanol in the range o 10-6 M AmB, using a 
1 cm path length cuvette. In the case of need of quantifying AmB below 10-6 M AmB a 
stationary cuvette may be used (19).  The use of electronic absorption for the AmB 
quantification was already described in the literature as a simple, reliable and cheap 
analytical method (20-23). 
 The AmB-SD products are sold as a lyophilized mixture of 50 mg AmB and 41 
mg SD (10, 24), to be dissolved firstly in 10 mL injection water prior to patient 
administration. Concerning drug label, results show that just one of the three products 
evaluated was in the concentration announced. Products A and B were more than 25% 
AmB concentrated than the labeled amount. Such results were reflected on the AmB 
aggregation state, once UV-Vis spectra of polyenes are very sensitive to conformation 
changes induced by molecular interactions (8). 
 It is known that AmB concentration is directly linked to the molecular self-
association (16, 25-27). The drug aggregates in aqueous media due to its chemical 
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characteristics. Aggregated and monomers species exhibit significantly different 
absorption spectra (7, 28) as it can be observed in the Figure 5. Besides of the bands 
characteristics of monomeric AmB, an intense band appeared at λ= 325 nm, counting for 
the molecular aggregated form (14, 18). So, in AmB-SD products the UV-Vis spectra is 
that of monomeric and aggregated AmB (27, 29). 
 In water, AmB dissociates from SD forming monomers and oligomers of various 
aggregation states (10). Indeed, in aqueous suspension, three forms of AmB coexist: 
monomers, water-soluble oligomers and non-water soluble aggregates (14, 25). In 
general, the degree of AmB aggregation is calculated by the ratio between the absorption 
of the aggregated band for the monomeric band, in this case Abs325 nm/ Abs408 nm (8, 17, 
18, 27). Figure 6 shows the results for such a calculation. In agreement with the literature, 
the degree of AmB aggregation increased according to the increase in drug concentration. 
 However, electronic spectroscopy is not the best way to differ aggregated species 
(18). Spectra of different organization forms can be recorded by many other spectroscopy 
techniques such as circular dichroisim (CD), fluorescence, Fourier transform infra red 
spectroscopy and Raman scattering (30). The CD of AmB-SD systems is expected to be 
a better tool for the evaluation of AmB aggregation than electronic absorption due to it is 
elevated sensitivity to environmental modifications (9, 15). Indeed, AmB contains many 
centers of dissymmetry. Then, the use of chiroptical spectroscopy techniques can provide 
additional insight in the nature of aggregation tendencies (7). By definition, CD is a 
measure of the differential absorbance between left- and right-circularly polarized light 
(31). Therefore, any modification on AmB conformation could be identified by CD (9), 
showing changes that would be undetectable by UV-Vis (18).  
 The spectrum for AmB-SD alone presents a strong dichroic doublet typical of 
AmB dispersed as oligomers (3, 9, 25, 26). The bisignated shape of the spectrum is an 
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indication of a multimolecular structure in which heptane chromophores are in excitonic 
interactions (3, 7, 15, 18). The specific nature of the CD signal results from the fact that 
neighboring molecule have preferred orientations (9). Moreover, the couplet shape is 
unique for both, specific structural aggregate or a mixture of several aggregates. Then, 
any changes in the shape could be taken as evidence for a change in aggregate type or 
assembly of aggregates (18). 
In agreement with the literature, results showed in the Figure 7a indicated that all 
AmB-SD products presented AmB in its molecular aggregated form. The signals were 
equal in shape but slightly different in intensity. It can be explained by the difference in 
AmB concentration between products (18). In fact, intensities decreased with the decrease 
on AmB concentration. However, when the intensities values were adjusted for the same 
concentration, by calculation, both intensity and shape were similar for all the products 
analyzed (Figure 7b). An indication that the products present same oligomeric species 
into the suspension (18). The spectra obtained by electronic absorption and CD looks like 
contradictory, since the UV-Vis showed difference in the aggregation degree and for CD 
sign just a slight difference in intensities was found. In fact, these spectroscopy methods 
do not monitors the same species (15). Bolard et al. (1980) (16) explained that at 
intermediate AmB concentration the peaks wavelength of these methods no longer 
coincide. Then, electronic absorption monitors the exact amounts of the different 
amphotericin B forms, while CD allows the detection of associated species in minor 
amounts.  
The increase in product dilution evidenced the AmB dissociation towards 
monomers (Figure 8). In fact, the affinity between AmB and SD is so week that under 
dilution they are completely dissociated (10). Reduction in CD amplitude is related to the 
formation of aggregates with lesser number of the molecule in the solvent (3). In fact, 
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there is an AmB concentration threshold around 10-7 M from where CD records 
performed under and above showed the drug as monomers and aggregates, respectively 
(27). This kind of experiment, using products dilution were conducted by CD because the 
disappearance of the dichroic doublet is much more easily monitored by this mean than 
by its corresponding excitonic absorption band (17). The disappearance of CD signal was 
demonstrated in our findings at 5x10-8 M AmB concentration (Figure 8), indicating that 
only monomers of AmB were found (9, 18, 25, 32).  
The nature of aggregates seems to be the same, once the ration between the 
positive and negative peaks of AmB CD couplet (~2) did not vary under dilution (18). 
According to the CD couplet signature, AmB molecules are aggregated probably as 
antiparallel dimmers (26). 
The aggregation state of the drug seems to have influence on the size of the 
systems. It can be observed in the Figure 9 that the evaluated systems are quite similar in 
size (~30 nm) concerning number of droplets. However, when volume is taken in account, 
the signal became bimodal with less intense peaks around 30 nm and more intense peaks 
in the range of 150 – 300 nm. Hartsel and Bolard (1996) (11) and Espada et al. (2008)(14) 
indicate the size of Fungizone® micelles as < 400 nm.  However, this kind of 
measurement could be not exactly reflex of the structure size (14) since the dilution of 
the system have direct influence on the disruption of  the micelle structure and AmB 
aggregation. 
The most important point concerning AmB aggregation state in AmB-SD systems 
is about the drug mechanism of action. Both, the pharmacological activity and the toxic 
side effects are strongly dependent on the AmB molecular organization (8, 33). It is well 
discussed in the literature that AmB binds to sterol membranes, forming pores in it and 
making possible the leakage of important ions or, more than that, in dependence of AmB 
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concentration, causing the disruption of the cell, with consequently cell death (15, 16). It 
has been proved that AmB-SD of high aggregation state is more toxic than the same 
mixture at lower aggregation state (4, 8, 14, 25). 
The drug bind to ergosterol and/or cholesterol is suggested to be the key for 
understanding the appearance of AmB side effects (4, 26). It is admitted that the 
interactions between AmB and sterols occur through hydrophobic interactions, where the 
seven conjugated AmB double bonds interacts with ergosterol or cholesterol (4). AmB is 
not specific for the binding to ergosterol, the sterol of fungi and protozoa cells. However, 
it has been demonstrated that when the drug is in its monomeric form, it is not able to 
cause toxicity for cholesterol-containing cells (4, 14). Then, the difference in AmB 
aggregation in products supposed to be equal could result in differences in the therapeutic 
response, incurring in patient’s hard side effects and consequently augmentation in the 
time of hospital housing. 
 
Conclusion 
To our knowledge, this is the first time that a comparison between AmB-SD 
micellar systems is made.  The overall results showed that the marketed products analyzed 
have similar mean diameter size, despite the unmatched labeled content. Only the product 
C was in the designated concentration of 5 mg/mL. Products A and B were more than 
25% up concentrated. All of the products were presented as a mix of AmB monomers and 
oligomers as expected, and the level of AmB aggregation was in accordance to the drug 
concentration. CD studies revealed that the same species of oligomers are presented into 
the three formulations. This study suggests, in the light of AmB aggregation that the 
AmB-SD systems in here evaluated cannot be interchangeable.  
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Abstract 
 
The amphotericin B (AmB) is a polyene antibiotic used to treat life-threatening systemic 
fungal infections. The drug is currently available as AmB-micelles and -lipid-based 
products. The micelles are a mix of AmB and sodium deoxycholate (SD), a biliar salt that 
acts as a surfactant. This is a quite simple delivery system, and its injection is responsible 
for important side-effects of the drug. The mild heating has been proved to improve the 
safety of AmB-SD micelles by the formation of super-aggregates. In this work we tested 
the possibility of super-aggregates formation from a liposomal system and tried to 
measure the energy involved in the super-aggregation process. In addition, the heated 
system was evaluated along the time, to evaluate the influence of the process on the drug 
stability. It was demonstrated that only AmB-SD micelles can form super-aggregates that 
improved the drug stability along the time. The process was accompanied of spectral 
changes by UV-Vis and circular dichroism (CD). These changes, caused by the mild 
heating seem to be irreversible.  Isothermal titration calorimetry (ITC) was not able to 
clarify about the energy spent/generated on super-aggregation process, but suggested that 
some energy is generated during the re-organization of oligomers towards monomers of 
AmB. 
 
 
 
 
 
Key-words: amphotericin B; micellar system; liposomal system; super-aggregates; 
circular dichroism; isothermal titration calorimetry; 
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Introduction 
The amphotericin B (AmB) molecule is an antibiotic discovered in the 1950’s and  
broadly used in the treatment of life-threatening systemic fungal infections up to now (1). 
More recently, the drug has been used to fight against the leishmanial protozoa, in 
refractory treatment with antimonials (2). 
Drug physico-chemical characteristics are marked by hydrophobicity, due to a 
polyene chain and hydrophilicity, due to a polyhydroxylated region. Besides, AmB has 
amphoteric character. All together are responsible for the poor solubility of the drug (3). 
Indeed, it is the main drawback to the development of AmB-containing pharmaceutical 
formulations (4).  
AmB was firstly marketed in the form of AmB-containing micelles, a mix of the 
drug with sodium deoxycholate (SD). In spite of the problems such as headache, nausea, 
vomiting, phlebitis and nephrotoxicity related to the AmB-SD micelles infusion, the 
product is commonly used, mainly in developing countries (5, 6). In the last decades, 
AmB-containing lipid-based products have been introduced in the market (7-9), 
increasing AmB safety, mainly by nanomodification (10-13). Indeed, the lipid systems 
developed are less toxic and have the possibility of improvement of doses, that was not 
possible for AmB-SD (8, 14). However, due to their cost, this sort of systems are not 
affordable for most of poor countries (4, 9).  
Strategies those are still in the field of research deal with the use of micelles 
themselves being diluted for other systems like nanoemulsions and microemulsions (6, 
15), as an attempt of de-aggregate the drug, delivering monomers of AmB instead of 
oligomers, proved to be more toxic AmB species (16). 
The mild heat of AmB-SD has been related to the formation of a different 
supramolecular organization of the drug. Through this process a new spectroscopic AmB 
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species with same efficacy and improved safety is born.  The structural re-organization is 
accompanied of increase in aggregates size and then, has been called as “super-
aggregates” (3, 17-20). 
The super-aggregates were proved to be formed from AmB dissolved in water 
(17) and most commonly, from AmB-SD (21), which is more convenient since it is the 
widely available form of AmB (9). From our knowledge, there is no reference about the 
super-aggregation from different AmB-containing systems. In this work we have applied 
the heat process to an AmB-SD as well as to an AmB-liposomal system. It was verified 
the capacity to form super-aggregates from them and the stability of the generated 
products along the time. In addition, we tried to measure the drug super-aggregation and 
de-aggregation energy by Isothermal Titration Calorimetry (ITC). 
 
Methodology 
Materials 
The AmB-SD micellar system used was Anforicin® B, a gift from Cristália 
(Brazil). AmBisome® was acquired from Gilead Sciences (USA). Methanol was HPLC 
grade from Merck® (France) and the ultrapure water was obtained by Milli® Q 
purification system. 
Products suspension 
 Both Anforicin® B and AmBisome® were prepared according to supplier’s 
recommendation. Briefly the yellow lyophilized powder was re-suspended in water for 
injection. Each vial was re-suspended in 10 mL water, reaching 5x10-3 M AmB 
concentration and reserved for further studies. 
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Preparation of AmB super-aggregates 
 The super-aggregates were prepared as described for Gaboriau et al (1997) (17) . 
After Anforicin® B and AmBisome® re-suspension, samples were placed in a water bath 
at 70 ºC (± 2) for 20 min and then reserved for further characterization. 
Super-aggregates characterization 
Spectroscopic studies 
 The AmB aggregation state was analyzed in the samples before and after heat 
process by electronic spectroscopy (UV-Vis) and circular dichroism (CD) (22, 23). 
UV-Vis analyzes were carried out in a PerkinElmer (France) spectrophotometer 
after 1000x dilution of the re-suspended product, using a 1cm length quartz cell in 
different days (D): D0; D3; D7; D14 and D28. 
CD transitions of AmB were recorded using a Jasco J-810 dichrograph (France), 
by using 0.1, 1, and 5 cm path length quartz cell, according to the sample dilution, in the 
first day of analysis. 
The wavescans for both, UV-Vis and CD were from λ = 300 to 450 nm. 
Drug degradation 
 The AmB degradation was evaluated by the decrease in drug absorption, 
calculated in this work as percentage (%) of remained AmB. Aliquots of the samples were 
diluted 1000x in methanol and read at λmax= 405 nm. The absolute absorbance value was 
taken and expressed as percentage. The first day absorbance was considered as 100% 
AmB and the next days’ percentage were calculated in function of the first day. 
Isothermal Titration Calorimetry studies 
 The ITC experiments were performed in a MicroCal® VP-ITC (Malvern) 
microcalorimeter. Briefly, 1200 µL of the AmB-SD system (5x10-3 M) was placed into 
the cell and left for 20 min, solution injections of 5μL where made for a continuously 
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rotating (264 rpm) syringe at time 0 and 20 min, in order to specify the beginning and end 
of the experiment. The titrations were performed at different temperatures: 40, 50, 60 and 
70 ºC.  
 ITC is supposed to measure directly the energetics (via heat effects) associated 
with reactions or processes occurring at constant temperature. The heat released or 
absorbed as a result of the reaction is monitored by this means (24). 
Afterwards, the liquid was recovered from the cell and analyzed by dynamic light 
scattering (DLS) at 173 º angle, 25 ºC in a Malvern Zetasizer Nano-ZS (France) for size 
measurement and UV-Vis, for molecular aggregation evaluation. 
 Additionally, a dilution assay was performed at 20 ºC. The AmB-SD samples were 
diluted from 5x10-5  to 5x10-8 M AmB by 148 injections of 2 μL water. 
 
Results 
Spectroscopic studies 
 The spectrum of heated and unheated AmB-SD and AmB-liposome were recorded 
by both, UV-Vis and CD spectroscopy.  
Figure 1 shows the electronic spectra of the systems in water. AmB-SD 
(Anforicin® B) presented bands at 326, 364, 385 and 408 nm. After heat treatment the 
first band was blue-shifted to 323 nm while the other bands remained unchanged. 
The liposomal system presented a main band at 322 nm and smooth peaks at 365, 
388 and 418 nm. The heat treatment did not shift any peak, in this case. 
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Figure 1. UV-Vis spectra in water for a) Anforicin® B and b) AmBisome® before 
(upper panel) and after (bottom panel) heating process, recorded along 28 days from the 
initial concentration of 5x10-6 M AmB. 
  
The spectra shape of AmB-SD was modified along the time for the unheated 
system. The peak at 326 nm was progressively decreasing in intensity while increasing at 
408 nm. For the heat treated system, it was observed a decrease in intensity for all bands 
along the time, spectra shape remaining unchanged. The liposomal system did not present 
any change. Besides, it was observed that both of systems presented slightly more intense 
peaks after heat treatment (Figure 1). 
322 
nm 
322 nm 
326 
nm 
323 
nm 
a) b) 
 94 
 
 The Figure 2 presents the drug CD spectra in water at three different 
concentrations, before and after heating treatment. 
Figure 2. AmB CD spectra in water for a) micellar and b) liposomal preparation. Before 
(upper panel) and after (bottom panel) heating process, in three concentrations. 
 
 The unheated micellar system presented an intense dichroic doubled centered at 
330 nm, with a positive band at 321 nm and a negative band at 335 nm, where the doublet 
intensity progressively decreased upon system dilution. After heat process, the dichroic 
doublet center was blue-shifted to 321 nm and positive and negative peaks shifted to 315 
nm and 333, respectively. Two interesting results were observed for the micellar system 
after heat treatment: dichroic intensity decrease and almost unchanged intensity upon 
dilution. 
a) b) 
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 The liposomal system did not change characteristics after heat treatment and 
dilution. The intensity was ~10 times lower than Anforicin® B and the dichroic doublet 
was centered at 328 nm, with positive and negative bands at 322 and 333 nm respectively. 
Drug degradation 
 The AmB degradation was followed by UV-Vis during 28 days. Drug 
concentration is given in percentage of absorption with basis in the first day’s absorption 
absolute value in methanol.  
As it could be observed in the Figure 1, the intensity of the AmB-SD systems in 
water decreased along the time while the liposomal system remained unchanged. Such 
behavior was a reflex of drug degradation, as demonstrated in Figure 3.  
 
Figure 3. UV-Vis quantification (%) of AmB-containing micellar and liposomal 
products. Heated (discontinuous lines) and unheated products were analyzed. 
 
 After 5 days in water solution, AmB-SD 14% degraded, while heated AmB-SD 
was 7% degraded. In the end of 29 days, the heated system presented 13% more drug than 
the unheated one. 
 The liposomal system was always upper than 94% drug content during the whole 
study, for heated and unheated systems. 
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ITC studies 
 As the super-aggregates were formed using AmB-SD, we tried to measure the 
energy of molecular re-organization of this system using four different temperatures, from 
40 to 70ºC. Figure 4 shows the thermograms for each assayed temperature.   
 
Figure 4. Thermograms of the Anforicin® B (5e-3 M) record in different temperatures: 
a) 40 ºC; b) 50 ºC; c) 60 ºC and d) 70 ºC. The injections define the begining and the end 
of the counted time (20 minutes). 
 
 The signal for all of experiments were too low, making impossible the 
measurement of the heat signal for any temperature tested. The two more intense signals 
refers to the injection moments used to indicate beginning and ending time points. 
 However, the collected samples changed in turbidity that reflected the increase in 
size, confirmed by DLS measurement (Figure 5).  
a) 
c)  
b) 
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Figure 5. Comparison of the size of an AmB micellar solution after heating process at 
four different temperatures by naked eye (upper panel) and DLS (bottom panel). 
 
 As the temperature increased, the size increased: stock solution (20 ºC) 12 nm; 40 
ºC – 18 nm; 50 ºC – 79 nm; 60 ºC – 122 nm and 70 ºC – 459 nm (size/number). 
 Besides, the drug aggregation peak was blue-shifted in different levels according 
to the temperature applied (Figure 6). 
 
Figure 6. Spectra of Anforicin® B solution (5x10-3 M AmB) heated at different 
temperatures in an ITC equipment. 
 
 Then, a dilution from aggregated to monomeric form was performed by water 
titration and the thermogram is depicted in the Figure 7. 
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Figure 7. Thermogram for the dilution of an AmB-SD solution, from 5x10-5 to 5x10-8 
M AmB. 
 Although the heat signal was too low, it can be observed that the heat was more 
pronounced in the beginning of the reaction. 
 CD spectra were recorded for the samples before and after dilution, evidencing 
the differences in the dichroic doublet in unheated systems, from AmB aggregated to 
monomeric forms (Figure 8). 
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Figure 8. CD spectra of AmB-SD solution as oligomer aggregates (5x10-5 M) and AmB 
monomers (5x10-8 M). 
 The concentrated drug presented a pronounced excitonic doublet while the diluted 
drug did not present any signal. 
 
Discussion 
Super-aggregates formation 
The AmB is a polyene macrolide antibiotic in which a hydrophilic and 
hydrophobic portion coexists (3). In the hydrophobic portion, there are seven double 
bonds that give a good spectroscopic fingerprint for this drug: a chromophore region 
absorbing light between 300 and 450 nm (25, 26).  
In the aqueous media, AmB can be found in equilibrium as monomers and 
aggregates, this last species could be soluble or insoluble in the medium (17, 18, 23). Due 
to the chromophore organization, each aggregation state exhibits an unique absorption 
spectrum (27). Sánchez-Brunete et al. (2004) (28) studied the different AmB aggregation 
states in aqueous medium. They have showed the spectra for monomers (λmax 363, 383 
and 406 nm), soluble aggregates (oligomers) (λmax 328 nm) and a new spectrum for a 
species that they have called as multi-aggregates (λmax 358, 370, 392 and 420 nm). 
However, shifts in the peaks could appear under specific conditions such as the presence 
-15
-10
-5
0
5
10
15
20
25
30
300 350 400 450∆
ε
x 
1
0
4
(M
-1
. c
m
-1
)
Wavelenght (nm)
5.10E-5 5.10E-8
 100 
 
of polar solvents, the method of preparing solutions, temperature changes (20, 23) and 
association with other lipids (9). 
In the Figure 1 it is showed the electronic spectra of AmB-SD and AmB-
liposomes before and after heat treatment. It can be observed that AmB-SD presents peaks 
for aggregates as well as for monomer species (28), while the liposomal preparation 
presents a main peak, blue-shifted, probably due to the interaction of the chromophores 
groups with the liposome-composing lipids and low signal for the red-shifted monomer 
peaks. 
Besides of electronic spectroscopy, circular dichroism (CD) is a very sensitive 
tool to identify the presence of aggregated AmB in the medium (20). A characteristic 
excitonic couplet in the CD signal is noted when the drug is aggregated (29-32) due to 
the many AmB centers of dissimetry (26). Then, the couplet is assumed to reflect 
excitonic interactions between AmB molecules within the aggregates (17). Therefore, any 
modification on AmB conformation can be identified by CD (30). In fact, Figure 2 
displayed a 10 times low signal for liposomal system, when compared to AmB-SD, 
reflecting the difference in aggregation between those systems. 
The AmB super-aggregates are formed under mild heating in the expenses of the 
drug smaller oligomers (mainly dimmers) and monomers (18, 19, 27) (Figure 9). The two 
most probable chemical modification caused by heating on AmB would be oxidation of 
the polyene backbone or lactone ring cleavage (9), both of them sensitive to spectroscopic 
methods. As they not occur, it is suggested that the changes are merely in the 
supramolecular structure (9, 20), which is reflected in a blue-shift on the drug spectrum 
by CD and UV-Vis (Figures 1 and 2) (17, 27). 
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Figure 9. Scheme of super-aggregate formation: AmB coexists as monomers and 
oligomers in solution; after mild heating super-aggregates are formed in the expenses of 
the previous AmB forms (Based on Gaboriau et al. (1997) (18)). 
 
The formation of super aggregates has been reported from AmB aqueous solution 
and mainly from micellar solutions (drug mixed with sodium deoxycholate) (3, 17-19, 
21, 22, 33). There is no report of AmB super-aggregates formation from liposomal 
systems. Maybe, because the super-aggregation is a strategy to lower the toxicity of the 
micellar systems and that lipid-based systems already present improved safety. But, on 
the other hand, it have to be taken in mind that in the liposomal system, AmB is strongly 
associated with cholesterol (14, 23, 34), making difficult AmB release upon dilution. This 
is probably why the CD signal is ~10 times lower than the AmB-SD signal (Figure 2): as 
the drug remains bound to the lipid, less oligomers are free in the medium to form an 
intense CD doublet signal. Consequently, the essential species above mentioned (AmB 
aggregates and monomers) for the super-aggregate formation are not available in the 
required concentrations.  
Moreover, there is no shift in both UV-Vis (Figure 1) and in the couplet former 
peaks (Figure 2), reinforcing the assumption of non-formation of AmB super-aggregates 
from the liposomal system. 
AmB oligomers AmB monomers 
70 ºC 
20 min 
 102 
 
After a mild heating, super-aggregates were formed  from AmB-SD systems as 
evidenced by the blue-shift on the electronic band from 326 nm to 323 nm (Figure 1) and 
also in the excitonic doublet observed by CD (Figure 2) (9, 17, 23). Indeed, increases in 
temperature enhance the hydrophobic strength while decrease ionic and polar 
stabilization. Then, the blue shift in the maximum band indicates a new aggregation form 
in which the chromophore groups are highly organized in a nonpolar environment, where 
the frequency of hydrophobic interactions is assumed to increase (17, 20, 27). 
Although the Bee-Lambert law does not hold in the case of CD for aggregated 
AmB (20), it is important to mention that the CD signal decreased after heating process. 
Such a behavior was also found by super-aggregates characterized by other researchers  
(17, 23). A change in CD bands amplitude is likely to reflect a change in the number of 
molecules in an aggregated form, and variations of the other spectral characteristics are 
related to conformational changes of aggregates (20). Decrease in CD doublet has also 
been explained by the increased size of super-aggregates, that makes a blue-shift on the 
electronic transition and could also be accompanied of weak CD doublets at lower 
wavelength (17). 
Stability after heating process 
The super-aggregates appear to be more stable than the previous system. In our 
study this assumption is supported for both, the maintenance of the electronic spectrum 
shape (Figure 1) and the low change in intensity of CD signal upon dilution (Figure 2) 
that happened only for heated AmB-SD and that is going to be discussed in the following 
lines. 
In the first case, it is seemed that the heat was able to change the AmB 
conformation in a stable way. Along the study, for the un-heated micellar system, the 
peak of aggregates decreased while the peak of monomers increased (Figure 2), 
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suggesting a modification on the aggregation state. The ratio between the peak of 
aggregates and that of monomers is an interesting tool to evaluate the degree of drug 
aggregation into the system (35, 36). In fact, when the concentration of the drug 
decreases, the balance between monomers and aggregates moves towards monomers (19, 
32).  However, for the heated system, both peaks decreased in intensity and the spectra 
remained similar in shape during the complete study.  
Diluting an aliquot of the sample in methanol and analyzing it by UV-Vis, it was 
confirmed that the heated system had its stability increased when compared with the un-
heated counterpart (Figure 3). The literature had already showed that heating AmB 
solutions increase its chemical stability for at least 2h (17). However, it is the first time 
that it is presented a study for such a long period as one month. 
Such a behavior can be explained by the mechanism of drug degradation summed 
with the dissociation of AmB species from the super-aggregates. The decrease in AmB 
concentration is a process dependent of oxygen, corresponding to the drug auto-oxidation, 
mainly related to the various oligomers types present in AmB-SD (9). Then, the increase 
in stability might be explained by the drug re-structuration itself. The super-aggregates 
would be a more cohesive particle, hiding the chromophore group and consequently 
lowering its exposure to the aqueous solvent and also acting as a reservoir, being slowly 
dissociated as monomers, those are not involved in auto-oxidation (17). 
Besides of electronic spectroscopy, it was observed that after heat treatment CD 
signal was quite constant even upon dilution (Figure 2), indicating that the drug remained 
associated in its new structure (37). This behavior is explained by Silva-Filho et al. (2012) 
(19) for the stronger bound of AmB to the surfactant when compared to un-heated system, 
while Brajtburg and Bolard (1996) indicate that the signal is constant due to 
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uniformization of the type of oligomers in solution (11). All together suggests super-
aggregates as more stable organization than the previous micellar system. 
The super-aggregates showed to be less degraded than the un-heated system. 
However, as the drug is in solution, drug degradation does not stop occurring. Recent 
studies have shown the possibility of freeze-drying AmB super-aggregates, maintaining 
its physical and biological features (3). 
 The liposomal system was stable along the study, once no differences in 
concentration were found among days and the heating process did not affect the system 
aggregation behavior.   
ITC experiments 
Super-aggregates formation 
Once observed that the super-aggregates only are formed from micellar systems 
of AmB, it was conducted a study seeking to measure the energy dispensed or generated 
during the AmB molecular re-organization.  
ITC technique is highly used for evaluation of molecular interactions or 
conformational changes based in the knowledge that any interaction can release or absorb 
heat (24). The titrations performed in this work were set at 40, 50, 60 and 70 ºC, 
considering that super-aggregation can also occurs at low temperature, spontaneously 
(17).  
Despite the sensibility of ITC equipment, the amount of heat generated/dispensed 
in the process was not enough for track any molecular re-organization. In the titrations 
obtained at different temperatures (Figure 4), it was possible to measure the two water 
injections performed in the beginning and end of the titration. However, the tracked heat 
during the 20 min does not show any significant heat peak. 
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The ITC recovered liquid evidenced physical changes in size at naked eye that 
was further confirmed by DLS size measurement. Siqueira et al. (2014) (3) have also 
reported a prominent increase in turbidity upon increased temperature, suggesting 
molecular structural re-organization.  
The size increased as the temperature increases: by naked eye, the cloudier the 
sample, the larger it was found to be. The mean size of the stock solution was around 12 
nm, and increased sequentially up to around 450 nm (volume/number), when 70 ºC was 
used in the heating process (Figure 5). Such an increase in size justify the name give for 
the new structure: super-aggregates (19). 
It is assumed that the size of AmB-SD increases along time, probably due to AmB 
release from the micelle and consequent aggregation. The heat process may accelerates 
the dissociation process from the SD micelles, being followed by AmB re-association (9). 
Such a greater size is responsible for an increase on the uptake of the drug by the cells 
(22). 
Previous studies have showed that thermal treatment does not induces molecular 
dispersion, but seems to increase the size of aggregates until flocculation occurs (17). 
Increasing the temperature upper than 75 ºC have been reported in the literature with loss 
of drug solubility (27), probably due to precipitation caused by increased particle size. 
Because of that, and also because that at 70 ºC practically all the self-associated form is 
converted in the super-aggregated form (17), this temperature was set as the best one to 
form super-aggregates. 
The same samples, recovered from the ITC experiments conducted at different 
temperatures were then analyzed by UV-Vis. It reinforced the role of the temperature in 
the formation of the super-aggregates.  
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Different level of blue-shift and drug aggregation were found in accordance to the 
temperature employed (Figure 6) (27). Gaboriau et al. (1997) (17) showed that solution 
absorption spectrum stop to change for temperature higher than 70 ºC, reinforcing the 
choose of such a temperature to super-aggregates formation. 
De-aggregation 
A final attempt to measure the energy of the aggregation process was tried by the 
inverse of the process: diluting an aggregated AmB-SD solution (5x10-5 M AmB) to the 
monomeric form of the drug, at 5x10-8 M AmB (Figure 7). Since the biding isotherms are 
defined in terms of reaction heats, allowing a direct estimation of enthalpy changes related 
to association/dissociation constant (24). 
Unfortunately, the heat measurement done by ITC was quite low and did not 
permit many inferences: the signal was more intense in the beginning of the dilution, 
suggesting that the molecular re-organization generates heat. Then, in the end of the 
dilution the signal was even weaker, probably due to the reduction in shocks of different 
organized oligomeric structures.  
Luengo-Alonso et al. (2015) (4) have performed studies in which AmB (1.1 x 10-
5 M) was de-aggregated with PEG5kDa-cholane (0.6 x 10
-3 M). The isothermal results 
highlighted the complexity of AmB interactions of AmB, which takes place with different 
AmB soluble species. 
Despite the failure of measuring the energy involved in the de-aggregation 
process, CD spectra demonstrated that, in fact, the drug changed its conformation upon 
dilution, from aggregated to monomeric form (Figure 8). The monomeric units do not 
presents specific optical activity (17) (parallel transition moments do not lead to excitonic 
CD), while the intense CD couplet is explained by interactions between the small units 
(20). 
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Conclusion 
The overall results showed that the formation of super-aggregates is possible by 
heating AmB-micellar, but not liposomal systems. The process is responsible for the 
increase in size of the nanostructures. Such an increase was dependent on the temperature 
applied in the process. The super-aggregates seem to play an interesting role improving 
the stability of the drug along the time, since the new structure was maintained for at least 
28 days, although drug degradation occurred also for super-aggregates. Unfortunately, 
ITC experiments were not able to accurately measure the heat involved in the process of 
super-aggregates formation. However, it seems that the de-aggregation generates heat, 
that becomes weaker when the drug is presented as monomers. Finally, it is assumed that 
super-aggregates are less toxic than AmB aggregates, once its reorganization do not like 
to have the propensity of reconverting to the toxic soluble oligomer species. The effect of 
drug reservoir reported to super-aggregates means the release of a limited amount of 
monomeric AmB to the medium, that would increase both drug safety and efficacy, 
reinforcing the study of super-aggregates as an alternative to toxic AmB-SD products. 
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SECTION III 
            INCORPORATION OF AMPHOTERICIN B INTO EMULSION 
SYSTEMS 
____________________________________________________________  
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BRIEFING 
 
 Emulsion systems are able to load hydrophilic and hydrophobic molecules, once 
they are systems composed of oil and water. Micro-emulsion is one type of emulsion 
characterized for presenting high amounts of surfactants and this fact helps this system to 
better penetrate into different barriers. Nano-emulsion, in turn, are mainly aqueous system 
composed of low amounts of surfactants. 
 These systems are eligible for the encapsulation of the amphotericin B (AmB), 
due to its physicochemical characteristics, the drug is supposed to be placed in the 
interface oil/water. 
 This section is dedicated to the AmB incorporation into emulsion systems. The 
first chapter is a scientific report about the details of the drug loading into nano- and 
micro-emulsion. The drug aggregation state into these systems is presented in the first 
chapter for the nano-emulsion and in the second chapter for the micro-emulsion. The 
second chapter was conducted in collaboration with other Ph.D student from the LaSiD 
(Mr. Walteça Silveira) and present applications for AmB-loading micro-emulsions 
treating fungal infections.  
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CHAPTER IV 
AmB loading into micro- and nano-emulsion systems 
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 AmB loading into micro- and nano-emulsion systems 
(Scientific Report) 
 
Introduction 
 The “Laboratório de Sistemas Dispersos” (LaSiD) is dedicated to the 
development of emulsion systems, aiming to carry many types of molecules, mainly those 
fragile (1-3) and insoluble (4-7).  
 Emulsions are biphasic systems, composed of oil and water, stabilized by a film 
of surfactant molecules. These systems can be thermodynamically stable (e.g. micro-
emulsions) or unstable (e.g. nano-emulsions, real emulsions). Nano-emulsion systems, in 
spite of being thermodynamically unstable, are considered to be kinetically stable, due to 
their small droplet size. The main instability phenomena playing in this case is Ostwald 
ripening (8). 
 Once emulsion systems present both aqueous and lipid phases, the incorporation 
of different kind of substances of hydrophilic and hydrophobic character is believed to be 
possible (9). In this scenery, emulsions are suggested to be promising carriers for 
amphotericin B (AmB), a molecule of 924 Da, counting with a hydrophobic chain and 
polyhydroxylated region (10). 
 Indeed some studies have been dealing with emulsions as carriers for AmB 
delivery by different administration routes (4-6, 11-13) 
 In this work, the incorporation of AmB into nano- and micro-emulsion is reported, 
evidencing the limit of drug loading according to the system and the correspondent drug 
aggregation state. 
 
Methodology 
Micro-emulsion preparation 
 The micro-emulsion system was prepared based on the work of Silveira et al. 
(2016) (4) (complete work in the next chapter), with some modifications. Briefly, Lipoid® 
S100 and water were weighed in a flask and left under magnetic stirring up to the 
formation of a milky suspension. Then, Tween® 80 was added to the suspension and left 
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under stirring. Finally, Miglyol® 812N was added to the mixture that was homogenized 
by cycles of probe sonication (1.5 min) and ultra-sound bath (3 min). At least three cycles 
were needed. 
 
Table 1. List of ingredients for micro-emulsion prepare. 
Ingredient (%) 
Miglyol® 812N 
Tween® 80 
Lipoid® S100 
Water 
11 
14.7 
6.3 
68 
 
 The full characterization of this micro-emulsion system is presented in the next 
chapter. 
Nano-emulsion preparation 
 The nano-emulsion was prepared based on the work of Silva et al. (2016) (2) 
(Complete work in appendix). Briefly, the water phase composed of Tween® 80 and water 
was weighed and homogenized, under magnetic stirring. The oil phase, comprising Span® 
80 and Miglyol® 812N was weighed and homogenized into another flask. The aqueous 
phase was poured into the oil phase and sonicated for 4 min in a cold water-bath and 
reserved for further use. 
 
Table 2. List of ingredients for nano-emulsion prepare. 
Ingredient (%) 
Miglyol® 812N 
Tween® 80 
Span® 80 
Water  
5 
1.2 
0.8 
93 
 
 Two incorporation ways were tested for nano-emulsion. In the first method, the 
system was produced and then the drug was incorporated, this method will be represented 
in the results as “Nano + AmB”. In the second method, AmB was solubilized in water 
before nano-emulsion preparation, this formulation will be represented as NanAmB. 
Solubility test 
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 AmB solubility was tested in water, micro- and nano-emulsion, adapted from 
Mazerski et al. (1990) (14). 5mg AmB was added for each mL of liquid and homogenized 
under magnetic stirring. Determined volumes of NaOH 1N was added to the mixture and 
then centrifuged, 10 000 rpm, 5 min. After each centrifugation, an aliquot was taken from 
the supernatant and diluted in water for drug aggregation assessment and in methanol, for 
drug quantification. In case of pellet formation, more NaOH was added, the pellet 
resuspended restarting the process up to no pellet was formed or maintenance of 
supernatant drug concentration. 
AmB aggregation state and concentration 
 These studies were fully described in the Chapter II. Briefly, the drug 
concentration was evaluated by UV-Vis, using a calibration curve constructed in 
methanol, at 10-6 M AmB range. The aggregation state was evaluated for both, UV-Vis 
and circular dichroism (CD). 
Droplet size measurement 
 Measurements were made by dynamic light scattering. Samples were diluted 200-
times in pure water before analysis. 
 
Results and Discussion 
Drug solubility 
It is well described in the literature that AmB is water-soluble in alkaline pH, 
mainly above pH 10 (14). We were wondering if importance would be credited for the 
pH value or for the alkaline agent concentration. Then, in the drug solubility study the pH 
was evaluated after each NaOH (1N) addition and the results are displayed in the Table 
3. 
Table 3. Relation between alkaline agent volume and solution pH. 
NaOH (µL)* pH** SD (±) 
0 4,5 0,021 
5 11,2 0,008 
10 11,6 0,005 
15 11,8 0,031 
20 12,0 0,027 
 117 
 
25 12,2 0,008 
30 12,3 0,006 
40 12,5 0,006 
* 1N solution; ** average; 
If just the pH value would be considered for drug solubilization, we could assume, 
from the Table 3, that de addition of 5μL NaOH 1N would be enough to solubilize the 
drug in the medium. However, we have found that adding this NaOH quantity was not 
enough for full drug solubilization. Besides, the amount of alkali agent interfered on the 
AmB aggregation state (Figure 1). 
 
 
Figure 1. AmB solubilization in function of NaOH 1N addition and its influence on the 
drug aggregation state. 
 
The solubilization increases with the increment of NaOH concentration in the 
medium, reaching a plateau after 15 μL of alkali agent addition, in which 100% drug was 
in solution. It was observed that after total drug solubilization (achieved after 15 μL 
NaOH addition) the increment in alkali agent influenced on the aggregation state. In the 
beginning, drug was solubilized and presented mainly as AmB aggregates. In the end, 
when an excess of NaOH 1N was added, the drug was mainly as monomers and had its 
aggregation peak blue-shifted, indicating a different form of drug association. 
Then, it was evidenced that not only the pH, but the concentration of alkali agent, 
plays an important role on AmB solubilization in aqueous media, evidencing the 
importance of the net charge inducing the solubility of the polyene antibiotic (14). 
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Results for the solubilization of the drug into the emulsion systems are displayed 
in the Figure 2. Nano-emulsion presented results quite similar to the water solubility, 
being able to solubilize up to 5mg AmB. In spite of solubilizing less amount of drug (up 
to 3mg/mL), AmB presented similar aggregation patterns into the micro-emulsion 
system, with bands of aggregates and monomers (Figure 2).  
 
Figure 2. AmB solubility profile in nano- and micro-emulsion. The percentile of drug 
solubility (5mg/mL max) is showed in the upper panel and the aggregation pattern in 
function of the added NaOH 1N, by UV-Vis, is presented in the bottom panel. 
 
 The fact that same concentration of alkali agent was needed to solubilize the drug 
in water and in nano-emulsion could be due to the high water content (93%) in this 
system. However, the excess of NaOH did not cause changes in the aggregation pattern 
of the drug. Probably because AmB was associated with the lipids into the nano-emulsion 
system. 
 Micro-emulsion 
 119 
 
 The maximum drug solubilization in micro-emulsion was around 60%. However, 
the drug aggregation pattern was similar to that of nano-emulsion. The lower amount of 
water and greater amount of other components that are placed in the interface oil/water 
help to explain the solubilization rate into this system. A fully study concerning AmB 
loading into micro-emulsion is presented in the Chapter VI of this thesis. 
AmB-loaded nano-emulsions 
 As mentioned in the methodology, the loading into nano-emulsions was done in 
two ways. In the first loading method, the drug was incorporated after the prepare of the 
system (Nano + AmB). We have tested if the amount of drug loaded has influence on the 
size of the system (Table 4) and also in the AmB aggregation pattern (Figure 3). 
 
Table 4. Droplet size and polidispersity index (PdI) of nano-emulsion loaded with 
different amounts of AmB. 
Sample Z-Ave 
d.nm 
SD PdI SD 
Nano + 0,5 mg AmB 163,0 0,44 0,131 0,016 
Nano + 1,0 mg AmB 163,7 2,79 0,132 0,011 
Nano + 3,0 mg AmB 163,0 3,29 0,122 0,014 
Nano + 5,0 mg AmB 162,8 1,96 0,147 0,015 
 
 
Figure 3. AmB aggregation pattern according to the drug concentration loaded into the 
nano-emulsion. 
 The amount of drug loaded into the nano-emulsion did not influence the droplet 
size. However, as the amount increased, peaks of drug association emerged (15). 
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 After drug loading, at high pH, the system was neutralized. During this process 
the AmB aggregation pattern changed (Figure 4). 
 
 
Figure 4. Change of drug aggregation pattern into nano-emulsion according to the pH. 
 
 When the drug is loaded, at high pH, it is mainly as monomers. Then, at neutral 
pH, the drug is associated to the lipids or self-associated, being blue-shifted in the UV-
Vis spectra. 
Compared to the blank system, the drug incorporation caused an increase in size 
of about 10 nm and drastically decreased de zeta potential of the system (Figure 5). 
 
 
Figure 5. Characterization of nano-emulsion before and after AmB loading. A) zeta 
potential; B) droplet size. 
 
 These behaviors might be explained by the AmB placement mainly at the droplet 
oil/water interface. Increasing the thickness of the surfactant layer and as the drug is 
ionized, it contributes to the negative zeta potential. 
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
0,45
300 350 400 450
A
b
s 
(A
.U
.)
nm
Nano + AmB pH 7
Nano + AmB pH 12
 121 
 
 Another way of loading AmB into the nano-emulsion was preparing the system 
with an aqueous solution of the drug. Such approach produced a system in which the drug 
was loaded in a different aggregation pattern (Figure 6). 
 
 
Figure 6. AmB aggregation pattern into NanAmB according to the pH. 
 
 This new aggregation state has been reported in the literature as poly-aggregates 
of AmB (16). Interesting, the pattern did no change according to the pH. 
 This form of AmB aggregation has been reported as less toxic than the other 
associated forms in vivo, permitting and alternative dosing regimen (17) . 
An experiment using circular dichroism (CD) evidenced the differences on the 
structural arrangement of the drug into both types of nano-emulsions (Figure 7). 
 
 
Figure 7. CD spectra of blank nano-emulsion (Nano) and after AmB loading by two 
incorporation methods. 
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 The nano-emulsion free of AmB did not present signal by CD analysis. When 
loaded into the systems, the drug gives a bisignated spectra and the mismatch of intensity 
and shape evidences the difference on the arrangement of the drug into the systems. 
 The multi-aggregation pattern of the drug into NanAmB was reflected on the 
emulsion droplet size (Figure 8). 
 
 
Figure 8. DLS analysis of blank nano-emulsion and AmB-loaded systems during 
(NanAmB) and after (Nano + AmB) nano-emulsion preparation. 
 
 This result is in agreement with Espada et al. (16), who has studied the 
physicochemical and toxic characteristics of poly-aggregated AmB. 
 
Concluding remarks 
 The AmB loading into emulsion systems is promising, once they are of easy 
prepare, of high water content and built of low toxicity ingredients. Some experiences 
using nano-emulsion for carry AmB has been successful in the treatment of leishmaniasis 
(13) and fungal infections (18). Besides, emulsion systems open the possibility for AmB 
delivery by different routes such as topical (11) or even oral (6), an alternative for the 
therapy of nowadays, which is only possible by intravenous route. 
The systems developed in our laboratory were able to load up to 5mg/mL, same 
concentration found in the products marketed as micelles and liposome worldwide. The 
method used for AmB incorporation into nano-emulsions had influence on the drug 
arrangement, being possible to form poly-aggregates of AmB that was already ascribed 
in the literature as less toxic then the conventional dosage form of this drug. 
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 The overall results reported in here show the possibilities provided by emulsion 
systems on the search for an ideal carrier for the old molecule amphotericin B. 
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CHAPTER V 
Development and characterization of a microemulsion system containing 
amphotericin B with potential ocular applications 
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SECTION IV 
VEHICULATION OF AN AmB-SOLUBLE DERIVATIVE INTO A 
MICRO-EMULSION SYSTEM 
____________________________________________________________ 
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BRIEFING 
 
 The amphotericin B (AmB) physicochemical features cause the drug insolubility 
in various media, mainly in water. Such an insolubility influences on the development of 
new pharmaceutical products containing AmB, once the drug is soluble in a few types of 
solvents that are, in most cases, incompatible with the human use. 
 We have observed the aggregation behavior of alkaline solubilized AmB under 
the conditions of “super-aggregates” formation and developed a process in which the 
insoluble molecule passes through out, becoming soluble in water at neutral or slightly 
acid pH. 
 This section presents, in the chapter VI, a scientific report about the incorporation 
of an AmB-derivative, developed by our group (under protection) into a micro-emulsion 
system. 
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CHAPTER VI 
Microemulsion encapsulation of an AmB soluble derivative 
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Microemulsion encapsulation of an AmB soluble derivative 
(Scientific Report) 
 
Introduction 
The amphotericin B (AmB) is a polyene macrolide antibiotic which presents 
amphoteric and amphipathic character. Such features make difficult the drug load into 
pharmaceutical systems. Then, the development of drug derivatives has been tried as an 
attempt of improving drug solubility in the last decade (1, 2). 
Our research group developed a water-soluble AmB derivative by following 
simple physical and chemical steps of drug modification (in process of patenting). When 
compared by infra-red spectroscopy, the interaction C=O is lost during the derivation 
process (Figure 1). 
 
 
Figure 1. Infra-Red spectra of AmB (blue line) and its soluble derivative (red line). The 
lost of a signal band is evidenced. 
 
This derivative product presented the same spectrum of the parent molecule by 
UV-Vis, evidencing no changes in the polyene chain when dissolved in organic solvents 
(data in Chapter VIII). 
Emulsion systems are composed mainly of water and oil, and among the possible 
emulsion systems, microemulsion has been already used for loading AmB (3-7).  Indeed, 
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the molecule hydrophobic part might interacts with the lipids of the system, being 
supposed placed at the oil/water interface. 
We hypothesised, in view of the polyene chain maintenance, the derivative could 
also be placed in the interface   oil/water of emulsion systems. Therefore, the aim of this 
work was to encapsulate the AmB-derivative into a microemulsion without using organic 
solvents neither pH changes and evaluate the derivative aggregation state into the system. 
 
Methodology 
 
Materials 
Amphotericin B (99% purity) used for the derivative preparation was from 
Indofine Chemical Company (USA). Tween® 80 was from Sigma-Aldrich (USA), 
Lipoid® S100 was from Lipoid (Germany). Miglyol® 812N was a gift from Sasol 
(Germany). The ultra-pure water was obtained by Milli® Q purification system. 
 
Microemulsion production 
The microemulsion was prepared as described elsewhere (3), with some 
modifications. Briefly, Lipoid® S100 (6.3%(w/w)) was dissolved in water (68%(w/w)) under 
magnetic stirring up to the formation of a milk liquid. Then, Tween® 80 (14.7%(w/w)) and 
Miglyol® 812N were added to the mixture that was sonicated during 1.5 min using a probe 
sonicator Vibra-Cell 75041 (Bioblock Scientific, France), followed by 3.0 min of 
ultrasound bath USC-1800A (Unique, Brazil). Three sonication cycles were enough for 
microemulsion preparation. 
 
Drug encapsulation 
The soluble derivative was weighed to the corresponding weight of 1mg AmB and 
directly added to the microemulsion. Mechanical stirring was applied by using magnetic 
bars, and the sample was left to homogenize for 1.0 min. Centrifugation at 10.000 rpm, 5 
min in a Gusto mini centrifuge (Heathrow Scientific, USA) was performed and three 
aliquots of supernatant were taken and dissolved in methanol to drug quantification by 
UV-Vis Lambda 25 (PerkinElmer, USA), using the equation: y=167782x – 0.0144 (R² = 
0.9996). 
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Spectroscopic characterization 
The loaded system was characterized in terms of drug aggregation by UV-Vis, 
using a Lambda 25 (PerkinElmer, USA) spectrophotometer and by Circular Dichroism 
(CD), using a J-810 (Jasco, USA) dichrograph. 
 
Results and Discussion 
 
The AmB derivative was easily dispersed into the microemulsion system. Any 
precipitation was found after centrifugation and 100% drug was recovered, as measured 
by UV-Vis.  
The AmB-derivative molecular spectra after microemulsion encapsulation 
showed peaks related to drug monomers as well as a shoulder in the region of aggregates 
(Figure 2). 
 
Figure 2. UV-Vis spectrum of AmB-derivative-containing microemulsion diluted in 
water. 
 
This behavior of aggregation was quite different from the one of the derivative in 
water, in which the molecule was mainly aggregated, in spite of being soluble (data on 
Chapter VIII). In fact, although both media were aqueous, the derivative aggregation state 
changed from the dilution in water to the dilution in microemulsion. A scheme is showed 
in the Figure 3. 
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Figure 3.  Scheme of AmB derivative aggregation in water and in microemulsion 
medium. 
 
As the polyene chain was not damaged, the derivative may do hydrophobic 
interactions, self-aggregating, as occurs with the parent molecule, AmB. It is supposed 
that the derivative hydrophobic part interacts with the microemulsion lipid core, being 
placed at the interface oil/water, mainly as monomers. 
Once water counts for the main component of the microemulsion system, some 
derivative may be self-aggregated and dissolved into the system aqueous phase, 
responding for the shoulder found by UV-Vis in the region of AmB aggregates. 
The aggregation state can be also observed by CD studies due to AmB many 
centers of dissymmetry. Then, chiroptical spectroscopy techniques can provide additional 
insight in the nature of aggregation tendencies (8). 
The encapsulation also changed the derivative CD spectra in water. Before 
encapsulation, one positive peak was found in addition to the characteristic excitonic 
doublet (data on Chapter VIII). This behavior changed and the signal of the 
microemulsion-encapsulated derivative was quite similar to the one of the parent 
molecule, which was re-analyzed after one week (Figure 4). 
 
Water Microemulsion 
AmB derivative Oil droplet Surfactant 
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Figure 4.  CD spectra of AmB-derivative encapsulated in microemulsion. Full line 
represents Day 0 and dotted line, Day 7. 
 
The excitonic doublet formed could be related to self-aggregation as well as 
complexation of the drug with the lipids composing the emulsion system. Our finds 
suggest that the encapsulation was maintained at least for one week, since the doublet did 
not change in shape and/or intensity along time. 
 
Concluding Remarks 
 
It can be concluded that the AmB-derivative may be encapsulated into the 
microemulsion by simple magnetic stirring, without the need of organic solvents neither 
alkali agents, common strategies applied to the parent molecule, AmB. 
The encapsulation was responsible for a change on the aggregation behavior 
towards derivative monomerization, in spite of observation of some signal of derivative 
aggregates in the aqueous medium. 
Finally, it was demonstrated that the encapsulation maintained the derivative 
stability into the system for at least one week. 
The overall results motivate us to evaluate the efficacy and toxicity of this AmB-
derivative microemulsion-encapsulated, as a possible agent for the treatment of fungal 
and protozoa infections. 
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Amphotericin B (AmB) has been used since the discovery in the 60’s of its 
efficacy in the treatment of fungal infections. However, because of unusual and specific 
physicochemical features, not many products have reached the market, due to formulation 
issues. Indeed, for at least 25 years the micellar system launched in 1966 (Fungizone®) 
has long remained as the only clinical option before the arrival of new formulations in the 
90’s. After Fungizone’s patent expiration, at least 15 generic products appeared in the 
market. The emergence of these products raised the doubt about the use and 
interchangeability between them. In spite of these issues, different micellar systems are 
still present in the market, being an inexpensive alternative to the treatment of fungal 
infections and leishmaniases, mainly in the developing countries. 
 
 Interestingly, only few cases of resistance have been reported for this drug along 
the time. This reason, besides of the high drug efficacy, have boosted researchers to 
develop new strategies for AmB formulation, aiming to control its release in 
physiological environments, aiming mainly to reduce drug toxicity and medicine costs 
besides of providing safer products that would be administered by other routes than 
parenteral delivery. This research effort has led in the 1990’s to the launching of new 
AmB-based products, including: Abelcet® (1995), Amphotec® (1996) and AmBisome® 
(1997). Such products had mainly improved drug safety but were also very costly 
compared to Fungizone®.  These advances in drug delivery of AmB have been made 
possible both by a better understanding of AmB behavior at molecular level and the 
rationale development of formulations based on this knowledge. 
 
 The drug mechanisms of action is depicted in the Figure 1, an updated scheme in 
which AmB molecules are able to interact in different ways with sterols, and particularly 
with ergosterol, which is specific from parasitic membranes, leading not only two the 
creation of ionic channels within the membrane, but also to direct interactions with 
ergosterol out of the membrane, leading to membrane depletion. Even, the formation of 
“sponges” made of ergosterol amphotericin B, outside of the parasitic membrane have 
been recently described by Anderson et al. (2014) (1). 
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Figure 1. Molecular structure of amphotericin B and ergosterol and proposed unifying 
model for amphotericin B antifungal activity involving two complementary AmB 
mechanisms of antifungal activity including membrane permeabilization (1), AmB 
ergosterol binding (2), and sterol sponge formation (3). 
 
In this revised model, these authors wrote that: “In the widely accepted ion 
channel model for its mechanism of cytocidal action, amphotericin forms aggregates 
inside lipid bilayers that permeabilize and kill cells. In contrast, (the authors) report that 
amphotericin exists primarily in the form of large, extra membranous aggregates that kill 
yeast by extracting ergosterol from lipid bilayers.”(1) 
 
It is important to note that membrane permeabilization leads to different types of 
ion channels formation in ergosterol containing membranes (2), as depicted in Figure 2. 
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Figure 2. Scheme of ion channel formed by AmB membrane permeabilization. 
 
In view of these activity pathways, it is therefore not surprising that any 
modification in the parasitic cells membrane environment is likely to affect both AmB 
killing activity and toxicity. Therefore, coming to AmB formulation issues, it is not 
surprising that most of researchers in the field cared about the aggregation state of the 
drug into the carrier and about the optimal mean to control the aggregation state of AmB 
in physiological media, since the activity and the toxicity are linked to the drug molecular 
arrangement in the medium. In fact, considerable knowledge has now been gained 
concerning the biophysics of AmB aggregation, which should have to be taken in account 
during the development of original AmB formulations.  
 
Figure 3 schematically depicts how an AmB-containing formulation, when placed 
in a physiological medium after delivery to patient, will give rise to a complex equilibrium 
between monomeric AmB (i.e. single molecule in water), dimers and different types of 
aggregates.  In turn, these different AmB species constituting this equilibrium will interact 
with fungi membrane ergosterol by different mechanisms as discussed above.  
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Figure 3. Schematically, after AmB-containing formulation delivery, complex 
equilibria are created between monomeric, dimeric and aggregates states.  In turn, these 
species interact with fungi membrane ergosterol by different mechanisms, including 
ion-pore formations within the membrane, ergosterol-AmB complexes adsorption at 
membrane surface or creation of large ergosterol-AmB “sponges” outside of the fungi, 
all mechanisms leading to kill the parasite. 
 
1. Attempts to control AmB aggregation state and release from pharmaceutical 
formulations 
 
 Not surprisingly, since the molecular state of AmB in formulation could be a 
critical parameter for releasing AmB in a molecular form favorable to cytotoxic activity, 
many formulation strategies have been proposed, which have been reported in the first 
chapter of this thesis (Pharmaceutical strategies for amphotericin B delivery), including: 
(i) micellar systems comprising polymers and co-polymers, biodegradable surfactants and 
even cyclodextrins; (ii) emulsified systems such as micro- and nano-emulsion, prepared 
from different oil cores and surfactants; (iii) liposomal systems using different types of 
phospholipids and preparation methods; (iv) nanoparticles made of different polymers 
and co-polymers, including different shapes and surface charges; and finally (v) various 
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other colloidal systems including  nanodisks, carbon nanotubes, nanogels and cochleates 
(3).  
 
In view of this variety of carrier systems, this thesis was dedicated to the study of 
AmB aggregation state into both marketed systems and newly conceived delivery 
systems. 
 
2. Variability of AmB aggregation state in marketed micellar pharmaceutical 
formulations 
 
 In the second chapter (Amphotericin B-containing sodium deoxycholate micellar 
systems: a comparison of physicochemical characteristics of marketed products) we have 
compared three micellar systems, having same composition and produced in three 
different countries: Brazil, India and France (4). 
 
 The labeled concentration of all products was 50 mg AmB per flask, that has to 
be diluted in 10 mL water (theoretical final concentration: 5mg AmB/mL). Quite 
curiously, two out of the three formulations were over-dosed, leading to over-
concentrated solutions (more than 25%), which may have consequences on the 
aggregation state after delivery. 
 
Indeed, the increase in concentration was correlated to an increase on the drug 
aggregation level, which was observed in UV-Vis spectra, highlighting the close 
relationship between concentration and drug aggregation. Meanwhile, the other physico-
chemical parameters analyzed such as aggregates size distribution and circular dichroism 
spectra showed no differences among products. 
 
The coexistence in the molecule of an hydrophilic and an hydrophobic moiety of 
the molecule makes that AmB molecules are prone to extensive self-aggregation. 
Consequently, in aqueous media, AmB can be found simultaneously in the form of 
monomers, dimers (head-head or head-tail) and aggregates, related by different equilibria. 
Talking about micellar formulations, when diluted (e.g. in physiological media), the drug 
is released in the medium and is likely to self-aggregate, accordingly to the concentration.  
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 Circular dichroism (CD) helped to clarify two important points. At the first, the 
reversibility of aggregation was demonstrated by diluting the different micellar systems, 
leading to AmB dis-aggregation, proving the aforementioned link between concentration 
and aggregation. The second point concerns the type and stoichiometry of oligomers 
formed.  Our results showed that they were of the same type in all the samples tested, 
despite the differences in drug concentrations. 
 
 Once CD and UV-Vis spectra were recorded for these samples, it is important to 
clarify that these methods no longer coincide. Electronic absorption measured by UV-Vis 
monitors the exact amounts of the different AmB forms, while CD allows the detection 
of associated species in minor amounts. 
 
 The nature of aggregates seemed to be the same, once the ratio between the 
positive and negative peaks of AmB couplet did not vary under dilution and according to 
the CD couplet signature, AmB molecules are aggregated probably as antiparallel dimers. 
 
 The size of the structures in solution is quite controversy since different values 
were obtained when DLS technique was employed, depending if the data were expressed 
in number or in intensity. It seems that the aggregation state played a role on the droplet 
size. However, as mentioned, this kind of measurement could be cautiously examined, as 
different bias could affect the estimation of the aggregates actual size. 
 
3. Formation of AmB super-aggregated from marketed micellar pharmaceutical 
formulations 
 
AmB super aggregates are known from the 90s, which result from the extended 
aggregation of the different species of the “classical” equilibrium between monomeric, 
dimeric and aggregated species.  Super aggregates have been initially produced by heating 
different existing formulations.  
 
It is well known that mild heating of AmB micellar solutions promotes AmB 
super-aggregation. Such super-aggregates are less toxic than the original preparation 
while keeping drug efficiency. Since, this behavior has been observed in other systems, 
including nanodisks (5), and more recently, attempts to engineer AmB-based 
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nanoparticles has been described (6).  The interest of these strategy is to create larger 
objects, which are known to demonstrate less toxicity against mamallian cells, while 
keeping antiparasitic activity. 
 
During the comparative study of different commercial formulations undertaken 
during this work, significant differences in the labelled drug concentration were observed, 
which were likely to directly impact AmB aggregation state. In the present work, we have 
studied the super-aggregation process of AmB-sodium deoxycholeate (SD) micelles and 
also evaluated the possibility of super-aggregation of the drug contained in a liposomal 
suspension (7). 
 
 In the case of the micellar AmB-SD solution, we have confirmed by UV-Vis 
spectrophotometry that the formation of super-aggregates was accompanied of an 
electronic blue-shift. The main peak centered at 326 nm moved towards 323 nm for the 
sodium-deoxycholate micellar system, confirming super-aggregation. In fact, the super-
aggregates formation could also be observed by naked eye, since the solution become 
blurred. Such an increase in turbidity was confirmed by DLS measurements. 
 
 From clinical experience, AmB liposomal suspension is a safe product and maybe, 
because of that, there are no reports in the literature describing super-aggregation 
formation with this kind of lipidic colloidal systems. Not very surprisingly, we observed 
no changes in spectral UV-Vis and CD signatures, suggesting that this system do not form 
super-aggregates on heating. We can hypothesize that super-aggregates heating of 
liposomal systems cannot lead to super-aggregation because the presence of oligomers 
and monomers in solution seems to be mandatory for the new entity formation. In the 
liposomes, AmB is strongly associated to the phospholipids and not released by dilution, 
as demonstrated by UV-Vis and CD, even along the time. Interestingly, this case study 
demonstrates that the physico-chemical state of aggregation within the formulation is able 
to control the nature of AmB equilibrium outside of the formulation. In the present case, 
if the reagents are not available, the new product cannot be produced. 
 
 An interesting point is that following the spectral changes of heated and unheated 
systems along the time, it was observed that the unheated systems balanced the ratio 
among dimers and monomers as a function of drug concentration. Then, the spectral shape 
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changed along the time. Such behavior was not observed when the system micellar system 
was heated. In this case there was a maintenance of the spectral shape along the time. A 
decrease in intensity was described for all the species, super-aggregates and monomers. 
This experience allowed us to suggest that the super-aggregates had a more cohesive 
structure, which resulted in an improvement of drug protection along the time. Heated 
systems after 28 days of shelf-storage, contained at least 10% AmB more than the 
unheated counterparts. 
 
4. Consequences of super-aggregates delivery in the body by parenteral routes. 
 
When AmB formulations are to be delivered by intravenous route of delivery, the 
behavior of super aggregates in the blood stream and possibly their recognition by the 
immune system may be an issue. Indeed, the possible recognition and capture of 
polymeric nanoparticles is a well know phenomenon.  As described by Coty et al. (2017) 
(8), the adsorption of specific plasmatic proteins at the surface of the particles may lead, 
or not, to their rapid recognition by specialized phagocytic cells in different organs, not 
only leading to fast clearance of the particles out of the blood, but also to unadequate 
organs/cells distribution within the body.  
 
 For this reason, we attempted first to get a better understanding of the architecture 
of AmB super aggregates, by attempting to measure the energy necessary to self-
aggregation by using an isothermal titration calorimetry equipment (ITC). However, the 
signals were quite low, just suggesting qualitatively that molecular re-organization 
generated heat but making impossible to gain any insight on the aggregation process 
itself. 
 
 However, we used a test known as the complement activation test, to evaluate the 
possible impact of  AmB aggregation on the immune response. This part of the work was 
conducted mainly by Dr. Marcelino, in which we collaborated on the aggregates 
characterization.  Briefly, preliminary results were obtained, which showed a correlation 
between the presence of AmB aggregates in (human) plasma and the activation of the 
immunological system (9). Independent of the formulation administered, when AmB is 
delivered by the intravenous route, AmB molecules are likely to bind to serum proteins, 
as well as self-aggregate, all phenomena which may considerably affect its uptake by 
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macrophage cell-like. From a practical point of view, immune system activation would 
be detrimental to safety of self-aggregated formulations and we suggest that these aspects 
should be explored in more detail for a better understanding. 
 
5. AmB incorporation into micro- and nano- emulsions and aggregation state control 
 
 Emulsions are systems able to carry lipophilic and hydrophilic molecules once 
they are composed mainly of oil and water. According to the composition, way of 
production and final characteristics, emulsions can be classified as micro-, nano- or 
regular-emulsion. Having in mind that drug aggregation can occur in very different carrier 
systems, we focused on AmB incorporation into micro- and nano-emulsion systems and 
followed the drug aggregation patterns into these systems (10). 
  
 We reported AmB incorporation into micro- and nano-emulsion systems, trying 
at first to figure out the solubility of the drug in the media by using pH alkalinization. In 
order to avoid the use of organic solvents, researchers take advantage of the alkaline pKa 
of the drug. Once the pH is higher than 10, AmB is mainly ionized and becomes soluble 
in the medium. However, up to the moment, there was not a study concerning the best 
alkali concentration in order to have AmB totally soluble or in the monomeric state. 
 
 In a first step, 1,48 .10-2 N NaOH alkalinization to pH > 11 helped to solubilize 
AmB, which existed mainly as dimers as demonstrated by UV-Vis spectrophotometry. A 
further increase in alkali (to 3,85 .10-2 N) was able to displace the UV-Vis spectra towards 
monomeric bands, indicating that not only the pH but the alkali agent concentration 
played a role on the drug solubility and aggregation. 
 
 In a second step, AmB solubility in nano- and micro-emulsion media was also 
evaluated. These emulsions consisted of medium chain triglycerides associated to 
different surfactants and water and had a constant composition in the whole study. It was 
found that the nano-emulsion was able to solubilize a higher amount of AmB (5 mg AmB) 
, when compared to the micro-emulsion (3 mg AmB). 
 
 Drug aggregation of AmB into the nano-emulsion increased as the drug 
concentration was increased similarly to the behavior of already reported for micellar 
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systems. Interestingly, the increase in droplet size when comparing loaded and drug-free 
droplets did not change in line with drug concentration. 
 
 When AmB was incorporated as a powder in the preparation, AmB was present 
into the nano-emulsion both as monomers and aggregates. Changing the incorporation 
process, when the drug was first solubilized into an alkaline aqueous phase, the drug was 
loaded as poly-aggregates, an AmB species already described in the literature and which 
have been described as being less toxic than the other AmB species. 
 
 When AmB was loaded into the micro-emulsion, AmB existed mainly in the 
monomeric form. The studies conducted in collaboration with Dr. Silveira (11) and Dr. 
Morais (12) showed how promising the AmB-containing micro-emulsion are.  In Dr. 
Silveira’s study the development of the micro-emulsion and all the characterization for 
its use in ocular infections are showed. The system was less toxic than the micellar 
formulation, having efficacy saved and even improved for the treatment of many fungal 
species. 
 
 Dr. Morais and co-workers have tested, in vitro and in vivo, formulations which 
would be efficient and inexpensive to treat leishmaniasis. They have tested heated and 
unheated micellar systems as well as the AmB-loaded micro-emulsion, in comparison to 
the liposomal system and no differences among the inexpensive systems (micro-emulsion 
and heated micellar system) and the liposomal products were found in toxicity and 
efficacy against L. donovani. 
 
Up to this moment we have been dealing with AmB into different carrier systems: 
micelles, liposomes, micro- and nano-emulsion. Caring mainly about characterizing the 
aggregation state of the drug into the system and on how the aggregation pattern could 
influence the drug toxicity and we have reported at least two successful uses of the micro-
emulsion system as an inexpensive alternative to the toxic micellar system. Then, we have 
loaded the AmB derivative into a micro-emulsion system(13). The new AmB species was 
easily dispersed in the micro-emulsion media, presenting UV-Vis spectra of monomers 
and a slight shoulder corresponding to AmB aggregates.  
 
7. Conclusions 
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 Issues concerning AmB loading into pharmaceutical systems stems from the 
unique, and unfavorable physicochemical features of this molecule. We hope that the 
present work will contribute to bringing new strategies for its delivery and opening 
possibilities for other administration routes, based on a better understanding of the 
relationships between AmB aggregation and formulation characteristics. 
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CONCLUSIONS  
The amphotericin B (AmB) molecule has been studied since its discovery, in the 
1950’s. Since that time many strategies have been considered aiming to improve drug 
availability for the clinics. The first developed product containing this drug was a micellar 
system produced as a mix of the biliary salt sodium deoxycholate and AmB. This system, 
available up to now, is of easy prepare and was largely produced for many pharmaceutical 
companies around the world, after Fungizone’s patent expiration. 
 In this work we made a comparison among Fungizone’s similar products, 
concluding that they are not equivalents physic-chemically. The ratio among monomers 
and aggregates is not reproducible on the different brands, even the labeled content was 
not respected in some cases, evidencing no interchangeability of tested similar products. 
Such result might be due to the difference on the production process or event to the raw 
material employed for the different pharmaceutical companies. 
 The AmB molecular re-organization by mild heating is responsible for the 
formation of the called “super-aggregates”. This procedure is already known for the 
scientific community and the decrease on the drug toxicity is attributed to the “super-
aggregated” conformation. Many researchers have demonstrated the possibility of re-
arranging the drug from micellar systems but no reports are found about forming “super-
aggregates” from AmB-containing liposomes. We have showed that the “super-
aggregates” are AmB species more stable than the ones of the original product and, for 
the first time, it was showed that is not possible to form “super-aggregates” from the 
liposomal system AmBisome®. 
 Lipid systems loaded with AmB are known for being safer than micellar systems. 
In fact, lipid complex and liposomes are available in the market and can be administered 
in higher doses without inducement of nephrotoxicity or other side-effects related to the 
infusion of AmB-micelles. Nevertheless, those are quite expensive products that impairs 
their broadly use, mainly in developing countries. 
 We have showed that AmB can be loaded into emulsion system of easy production 
and low cost, such are micro- and nano-emulsion. We have deepen the discussion about 
drug incorporation dependence on pH medium, highlighting the importance of the alkali 
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agent concentration. Besides, applicability of microemulsions as AmB-carrier was 
demonstrated as an alternative treatment for ocular infections and visceral leishmaniasis. 
 Finally, we understand that the main problems concerning AmB loading are linked 
to its low solubility. Then, we reported the production process of an AmB-soluble 
derivative that can be loaded into a micro-emulsion system, opening the possibility of 
administering the drug for the treatment not only for various fungal and protozoa diseases, 
but also for new administration routes. 
 The overall results presented in this Ph.D thesis are very important for the built of 
the scientific knowledge about antibiotics, mainly the amphotericin B, in which was 
evidenced that if one hand the drug aggregation state changes according to the system, on 
the other hand one can control these changes towards the aggregation states supposed to 
be less toxic and more efficient for the patients. 
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RESUME ETENDU 
Depuis la découverte de son activité antifongique dans les années 60, 
l’amphotéricine B (AmB) est devenue une molécule majeure de l’arsenal thérapeutique 
en parasitologie. Cependant, en raison de ses caractéristiques physico-chimiques tout à 
fait particulières et qui la distingue de nombreuses autres molécules actives, la 
formulation de cette molécule est extrêmement délicate et il n’existe qu’un nombre limité 
de spécialités commercialisées. Ainsi, depuis son lancement en 1966, la suspension 
micellaire Fungizone®, est restée pendant 25 ans la seule option médicamenteuse 
disponible.  Il a fallu attendre les années 90 pour voir arriver sur le marché d’une 
quinzaine de médicaments contenant de l’AmB et destinées à l’administration 
intraveineuse, après l’expiration des brevets couvrant la Fungizone®.  Cependant, la 
question de leur interchangeabilité s’est rapidement posée en raison des réelles difficultés 
de formulation de cette molécule.  Malgré ces difficultés, ces différentes formulations 
sont toujours disponibles sur le marché car dans de nombreux pays en développement 
elles représentent une alternative peu coûteuse en vue du traitement de diverses infections 
fongiques et principalement des différentes formes de la leishmaniose. 
 
 Au plan clinique, l’amphotéricine B est une molecule particulièrement 
intéressante car elle ne semble pas favoriser l’émergence de résistances majeures.  A ce 
jour, seuls quelques cas ont été rapportés. Dans ce contexte, et en raison de sa grande 
efficacité fungicide, de nombreux groups de recherche dans le monde ont intensifié leurs 
recherches en vue de proposer de nouvelles stratégies de formulation, avec simultanément 
pour objectifs : (i) de controller l’état moléculaire dans lequel l’AmB est libérée de ces 
formulations, (ii) de réduire la toxicité (importante) des formulations existantes, (iii) de 
diminuer le coût des formulations et enfin (iv) d’envisager l’usage de voies 
d’administration alternatives aux voies parentérales. Ces efforts ont conduit dans les 
années 90 à la mise sur le marché de différentes formulations lipidiques avec notamment 
l’Abelcet® (1995), l’Amphotec® (1996) et l’AmBisome® (1997). Ces formulations 
originales ont principalement permis d’améliorer la sécurité d’emploi en comparaison de 
la Fungizone®.  Il est important de relever combien la compréhension des mécanismes du 
comportement de l’AmB au niveau moléculaire, grâce aux progrès de la physico-chimie 
ont permis ces avancées thérapeutiques. 
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 Afin d’illustrer cela, la Figure 1 décrit schématiquement les mécanismes 
actuellement connus et par lesquels les molécules d’AmB interagissent avec les stérols et 
tout particulièrement l’ergostérol, qui est un stérol spécifiquement constitutif des 
membranes des cellules des parasites.  Pour expliquer l’action antifungique de l’AmB, 
les progrès récents en physico-chimie font appel, non seulement à la formation de pores 
ioniques transmembranaires, mais aussi à d’autres mécanismes impliquant une interaction 
avec l’ergostérol d’origine parasitaire et sa déplétion progressive de la membrane 
cellulaire, suivie de la mort du parasite.  
Dans ce dernier modèle, la production de véritables éponges constituées par l’agrégation 
de molécules d’ergostérol et d’AmB a récemment été décrite par Thomas M Anderson et 
al. 2014 (1).  
 
Figure 1 : Structures moléculaires de l’amphotéricine B et de l’ergosterol et modèle 
unifié décrivant les mécanismes de l’action antifongique par trois mécanismes 
complémentaires, avec : (i) la perméabilisation membranaire par l’insertion de canaux 
ioniques néoformés, (ii) la liaison d’une molécule d’AmB à une molécule d’ergosterol 
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et (iii), la formation extracellulaire d’éponges constituées d’ergostérol extrait de la 
membrane parasitaire et d’AmB. 
 
Dans leur vision de ces interactions, ces auteurs ont ainsi écrit : “In the widely 
accepted ion channel model for its mechanism of cytocidal action, amphotericin forms 
aggregates inside lipid bilayers that permeabilize and kill cells. In contrast, (the authors) 
report that amphotericin exists primarily in the form of large, extra membranous 
aggregates that kill yeast by extracting ergosterol from lipid bilayers” (1). 
 
On notera que deux types d’organisation (au moins) des canaux ioniques ont été 
décrites conduisant à la très grande toxicité de ces molécules pour les parasites (Figure 
2). 
 
Figure 2 : Schéme d’organisation moleculaire pour la formation des canaux 
ioniques d’AmB et ergosterol. D’après Gray et al. (2012) (2). 
 
Ainsi, l’état d’agrégation et la nature des interactions moléculaires avec les stérols 
gouvernent simultanément l’activité antiparasitaire, mais aussi la toxicité de cette 
molécule, de manière extrêmement fine.  Il n’est donc pas surprenant de constater que les 
formulateurs se sont attachés à concevoir des systèmes d’administration pour lesquels il 
soit possible de contrôler non seulement l’état d’agrégation dans la forme galénique, mais 
aussi dans les liquides physiologiques et au moins ceux du site d’administration, le sang 
quand il s’agit de la voie intra-veineuse.  De ce point de vue, il est permis d’espérer que 
les progrès considérables de ces dernières années dans la compréhension du 
comportement biophysique de l’AmB pourront être pris en considération dans le but de 
formuler des médicaments à base d’AmB, plus efficaces et plus sûrs. La Figure 3 
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représente schématiquement comment une formulation d’AmB, placée dans un milieu 
physiologique donné, va donner naissance à un équilibre complexe entre différents 
arrangements des molécules d’AmB, avec non seulement des molécules existant à l’état 
« monomérique », mais aussi des dimères et différents types d’agrégats. Toutefois, ces 
connaissances mériteraient largement d’êtres complétées.  Ainsi, force est de reconnaître 
que les interactions non spécifiques avec les molécules présentes dans le plasma sanguin 
sont fort peu étudiées.  Dans tous les cas, il faut considérer que ce sont ces différentes 
espèces d’AmB en équilibre entre elles qui vont ensuite interagir avec l’ergostérol 
originaire des membranes parasitaires, par les différents mécanismes décrits ci-dessus.  
 
 
Figure 3 : Description schématique des évènements survenant après l’administration 
d’une formulation contenant de l’AmB. Dans un premier temps, la dilution de la 
préparation aboutit à la formation d’un équilibre complexe entre les formes 
monomériques, dimériques (parallèles et anti-parallèles) et les états agrégés.  Ces 
différentes espèces interagissent ensuite avec l’ergostérol spécifiquement contenu dans 
la membrane des parasites, ce qui aboutit par différents mécanismes à la fragilisation de 
la membrane du parasite et à sa mort. 
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1. Contrôle de l’état d’agrégation de l’AmB dans les formulations pharmaceutiques 
et des modalités de sa libération.  
 
Dans ce contexte, il n’est pas surprenant de constater que de nombreuses stratégies 
de formulation de l’AmB ont été proposées.  Pour cette raison, le premier chapitre de ce 
travail a consisté à passer en revue ces différentes stratégies (Pharmaceutical strategies 
for amphotericin B delivery), et plus particulièrement : (i) les systèmes micellaires 
mettant en œuvre des polymères et des copolymères, des agents tensioactifs 
biodégradables et même des cyclodextrines, (ii) des systèmes émulsifiés du type micro- 
et nano-emulsions, préparées à partir de différentes huiles et différentes agents 
tensioactifs; (iii) des liposomes préparés à partir de différentes phospholipides et par 
différentes méthodes de préparation; (iv) des nanoparticules polymères à morphologie 
contrôlée (géométrie, taille, charge de surface) et enfin (v) divers systèmes colloidaux tels 
que des nanodisques, des cochleates, des nanotubes de carbone, des nanogels (3). 
 
La grande variété de ces systèmes conduit à s’intéresser à l’état d’agrégation 
permis dans chacun d’eux.  Toutefois, pour une question d’efficacité, nous nous sommes 
focalisés dans un premier temps sur la caractérisation de cet état dans les différents 
médicaments actuellement sur le marché et dans un second temps au développement de 
nouveaux systèmes. 
 
2. Variabilité de l’état d’agrégation de l’AmB dans les formulations micellaires 
commercialement disponibles. 
 
 Le second chapitre de ce travail (Amphotericin B-containing sodium deoxycholate 
micellar systems: a comparison of physicochemical characteristics of marketed products) 
a consisté à comparer trois système micellaires possédant la même composition et 
produits au Brésil, en Inde et en France (4). La dose nominale d’AmB affichée par flacon 
était de 50 mg, ce qui correspond à une concentration finale de 5mg AmB/mL après 
dilution dans 10 mL d’eau. 
Assez curieusement, deux de ces préparations se sont révélées sur-dosées, conduisant à 
des solutions sur-concentrées d’environ 25%, ce qui pourrait avoir des conséquences en 
terme d’agrégation après leur administration. Expérimentalement, l’augmentation de 
concentration constatée a conduit à une augmentation du niveau d’agrégation de l’AmB, 
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tandis que d’autres paramètres physico-chimiques tels que la taille et la distribution des 
agrégats, les spectres en dichroïsme circulaire (DC), ne présentaient pas de différences. 
 
 Toutefois, les études de dichroïsme circulaire (DC) ont permis de préciser les 
points suivants.  En premier lieu, la réversibilité de l’agrégation a été mise en évidence 
lors d’essais de dilution des différents systèmes micellaires, conduisant à la dissociation 
des agrégats d’AmB, confirmant l’existence d’une relation entre concentration et 
agrégation. Dans un second temps, les états d’agrégation obtenu à partir des trois systèmes 
ont été comparés mais n’ont pas montré de différences appréciables en dépit des 
différences de concentration.in drug concentrations. Cependant, la comparaison des 
spectres UV-Vis a permis de mettre en évidence des modifications que le DC n’était pas 
capable de révéler. La combinaison de ces études suggère néanmoins que les agrégats 
formés paraissent de même nature. Par ailleurs, le rapport des pics positifs et négatifs du 
couplet observé en DC correspondant à l’AmB ne variait pas au cours de la dilution, 
suggérant que les molécules d’AmB étaient probablement associées sous forme de 
dimères antiparallèles.  
 
 La taille des différentes structures formées en solution est assez mal connue et les 
données sont difficilement comparables aux données de la littérature dans la mesure où 
les mesures de diffusion dynamique de la lumière (DLS) sont parfois exprimées en 
nombre et parfois en intensité.  
 
3. Formation de super agrégats d’AmB à partir des formes pharmaceutiques 
commercialement disponibles 
 
L’existence de super agrégats d’AmB a été mise en évidence dans le courant des 
années 90. Ces structures paraissent résulter de l’agrégation d’agrégats préexistants et des 
autres espèces d’AmB présentent dans l’équilibre « classique » entre les formes 
monomériques, dimériques et agrégées.  Les super agrégats ont d’abord été produits par 
simple chauffage modéré des formulations micellaires existantes, notamment la 
Fungizone. La préparation obtenue est alors moins toxique alors qu’elle garde son 
efficacité thérapeutique. Par la suite, ce comportement a également été rapporté pour 
d’autres systèmes, tels que les nanodisques (5), et plus récemment, différents travaux ont 
été rapportés, consistant à préparer des « nanoparticules » d’AmB (6), ouvrant la voie à 
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diverses stratégies dans ce domaine, avec l’objectif de diminuer la toxicité de ces 
médicaments vis-à-vis des cellules des mammifères, tout en conservant l’activité 
antifongique.  
 
Ainsi, durant ce travail, nous avons étudier la capacité de différentes formulations 
commerciales constituées de micelles d’AmB et de sodium deoxycholeate (SD) et aussi 
de formulations liposomales à former des super-agrégats en les soumettant à un chauffage 
modéré (7).  
 
Dans le cas des solutions micellaires d’AmB et de déoxycholate de sodium, 
l’étude des spectres UV-vis a permis de mettre en évidence une dérive du pic centré à 326 
nm vers 323. Cette dérive (dite « dérive vers le bleu ») a ainsi confirmé l’obtention d’un 
état de super agrégation , d’ailleurs confirmé par une étude en DLS. 
 
L’expérience acquise en clinique a montré que l’AmB liposomale est un produit 
sûr.  C’est peut-être la raison pour laquelle jusqu’à présent leur capacité à former des 
super agrégats n’avait pas été évaluée. Quoi qu’il en soit, le chauffage modéré de la 
suspension liposomale n’a pas abouti à la formation de super agrégats détectables par 
spectrophotométrie UV Vis et/iu DC.  Ainsi, la présence de monomères et de dimères 
paraît indispensable à la formation des super aggrégats, alors que dans les formulations 
liposomales, les molécules d’AmB sont fortement associées aux phospholipides 
constitutifs du liposome, comme le montrent d’ailleurs des essais de libération par 
dilution des suspensions et au cours desquels la spectrophotométrie UV-Vis et le DC ne 
montrent jamais de libération d’AmB dans ces conditions.  De façon intéressante, cette 
étude du cas des formulation liposomales suggère donc que l’état de l’agrégation au sein 
de la formulation est parfaitement capable de contrôler la nature des espèces d’AmB 
disponibles à l’extérieur des objets, ainsi que leurs équilibres. 
 
 En suivant les changements spectraux des systèmes chauffés et non chauffés au 
cours du temps, il a été observé dans le cas des systèmes non chauffés que le rapport des 
dimères et des monomères s’équilibrait en fonction de la concentration en AmB.  Alors 
que des modifications de la forme des spectres ont été observées en fonction du temps, 
dans le cas des liposomes un tel comportement n’a pas été observé. Dans le cas des 
systèmes micellaires, une diminution des quantités de toutes les espèces décrites a été 
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observée. Ce réultat suggère que les super agrégats pourraient avoir une structure plus 
cohésives que les autres espèces connues.  D’un point de vue pratique, le chauffage 
présentat égaleemnt un avantage en terme de conservation de l’AmB puisque, après 28 
jours de stockage, les préparations contenant environ 10% d’AmB  en plus, 
comparativement aux contrôles non chauffés.  
 
4. Conséquences de la présence de super agrégats lors de l’administration 
parentérale des préparations. 
 
Lors de l’administration intraveineuse des formulations d’AmB contenant des 
agrégats ou des super-agrégats, la possible reconnaissance par le système immunitaire de 
ces particules étrangères à l’organisme doit être prise en considération. Ce phénomène 
connu dans le cas des microorganismes bien sûr, mais plus largement des nanoparticules 
administrées par voie IV résulte de l’adsorption de certaines catégories de protéines 
plasmatiques à la surface de ces objets qui sont alors rapidement phagocytées par diverses 
cellules spécialisées présentes dans différents organes.  Bien évidemment, il en résulte 
non seulement une diminution des quantités de molécules actives réellement disponibles 
aux sites d’action, mais aussi des modifications importantes de la distribution dans les 
organes ou les cellules concernées par l’ction ( ou la toxicité d’ailleurs).  
 
Afin d’étudier la possibilité de ce phénomène, nous avons tenté dans un premier 
temps de mieux connaître la structure des agrégats de molécules d’AmB en utilisant la 
technique calorimétrique de titration isotherme (ITC).  Cependant, les signaux étaient trop 
faibles pour être quantitativement exploitables. 
 
En revanche, la mise en œuvre d’un test d’activation du complément 
classiquement utilisé dans le cas des nanoparticules polymères, a été menée avec les 
différentes formulations étudiées afin d’évaluer l’impact de l’agrégation sur en terme de 
réponse immunitaire (8). Cette partie du travail a été menée en collaboration avec le Dr 
Marcelino et ma contribution à cette partie du travail a consisté à caractériser les états 
d’agrégation dans les préparations testées. Bien que préliminaires, ces premiers essais 
suggèrent que lorsqu’on place les différentes préparations contenant des agrégats au 
contact de plasma, on observe une activation du système du complément.  Cette partie du 
travail mériterait d’être développée dans la mesure où le déclenchement d’une réponse 
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immunitaire du fait de l’agrégation constituerait un effet négatif, en dépit d’autres 
avantages observés par ailleurs. 
 
5. Incorporation de l’AmB dans des micro- et des nano- émulsions et contrôle de 
l’état d’agrégation obtenu 
 
En fonction de leur composition, les émulsions constituées d’eau, d’huile et 
d’agents tensioactifs, peuvent donner naissance, non seulement aux émulsions 
conventionnelles, mais aussi aux micro-émulsions et aux nano-émulsions, selon leur 
nature et leur mode de fabrication. Dans la mesure où l’agrégation de l’AmB dépend 
fortement de la nature des systèmes auxquels elle est associée, nous nous sommes ainsi 
focalisés sur le cas des micro- et des nano-émulsions puisque ces deux systèmes 
constituent des systèmes différents de ceux étudiés précédemment, et avec pour objectif 
d’étudier l’état d’agrégation de l’AmB qu’ils permettent d’obtenir (9). 
 
Afin d’associer l’AmB à ces systèmes et alors qu’elle est naturellement insoluble 
dans les excipients qui les composent, nous avons étudié dans un premier temps la 
possibilité d’obtenir des solutions aqueuses alcalines d’AmB, facilement neutralisables, 
et de préférence à l’emploi de solvants organiques difficilement éliminables. Ainsi, nous 
avons montré qu’à pH = 11, et concentration 1,48 .10-2 N, l’AmB existait majoritairement 
à l’état de dimères.  Une alcalinisation supplémentaire (jusqu’à 3,85 .10-2 N) permet 
d’observer un déplacement supplémentaire du spectre UV-Vis indiquant l’apparition de 
monomères.  Il s’est ainsi révélé possible de trouver une concentration en base permettant 
d’obtenir la dissolution totale de l’AmB dans un état monomérique.  
 
Dans une deuxième étape, l’incorporation de l’AmB dans des micro- et des nano-
émulsions de composition équivalente et classiquement préparées à partir de triglycérides 
à chaîne moyenne (Mygliol 812) et de différents tensioactifs a été réalisée d’une part en 
incorporant l’AmB directement sous forme de poudre dans les préparations et d’autre 
part, par ajout de solutions alcalines d’AmB.  
 
Ainsi, quand l’AmB était ajoutée sous forme de poudre dans les nano-émulsions, 
l’AmB existait dans ces préparations simultanément à l’état de monomères et d’agrégats.  
En revanche, lorsque l’AmB était ajoutée sous forme de solution alcaline lors de la 
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préparation de la nano-émulsion, l’AmB apparaissait principalement sous forme de poly-
agrégats.  Comme cela a été discuté plus haut, l’existence de l’AmB sous forme 
d’agrégats est de nature à diminuer la toxicité des préparations.  Toutefois, le maintien de 
l’efficacité de ces préparations reste à démontrer. 
 
L’association de l’AmB aux micro-émulsions, permet d’observer qu’elle existait 
principalement sous forme monomère. Plus prometteuses, l’efficacité de ces micro-
émulsions a été évaluée en collaboration avec les Dr. Silveira (10) et Dr. Morais (11). 
Ainsi, l’étude du Dr. Silveira qui décrit le développement pharmaceutique et la 
caractérisation de ces systèmes, a montré le grand intérêt de cette formulation dans le 
traitement d’infections fongiques à localisation oculaire.  Ainsi, cette formulation s’est 
montrée moins toxique que les formulations micellaires commerciales, tout en ayant une 
efficacité maintenue, voire accrue selon la nature des espèces fongiques étudiées. Par 
ailleurs, le Dr. Morais et ses collaborateurs ont testé ces formulations, in vitro and in vivo, 
dans le traitement de la leishmaniose en leur comparant les systèmes micellaires non 
chauffés et chauffés, en utilisant les suspensions liposomales comme contrôle. Dans ces 
conditions, les microémulsions et les systèmes micellaire chauffés avaient un profil 
d’efficacité et de toxicité vis-à-vis de L. donovani comparable à celui des préparations 
liposomales.  Ainsi, ces micro-émulsions d’un coût très inférieur à celui des préparations 
liposomales, pourraient représenter une alternative très prometteuse aux formulations 
micellaires commerciales grâce à un profil de toxicité plus favorable (12). 
 
7. Conclusions 
 
 Les caractéristiques physico-chimiques de l’AmB sont à la fois à l’origine de ses 
propriétés fongicides remarquables, mais simultanément sont la source de sérieux 
problèmes en terme de formulation pharmaceutique. Au cours de ce travail, en nous 
basant sur une meilleure compréhension des phénomènes d’agrégation de l’AmB en lien 
avec les caractéristiques des formulations étudiées, nous espérons avoir contribué à 
clarifier les différentes stratégies d’administration actuellement développées, notamment 
la technique du chauffage modéré. Ce travail pourrait également ouvrir la voie au 
développement de stratégies d’administration par des voies d’administration alternatives 
aux voies parentérales 
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Stearylamine-containing cationic nanoemulsions as a promising carrier 
for gene delivery 
In 2013, when I have started my Ph.D studies, my mentor and I presented to the 
RENORBIO a project in biotechnology entitled “Cationic nanoemulsions for gene 
delivery: intracellular process and in vitro/in vivo evaluation of gene expression”, a 
natural continuation of the work developed for my master degree, in which we have 
developed a cationic system able to pack a plasmid DNA, clarifying the physical factors 
influencing the genetic material compaction into a pharmaceutical system. 
 Still in the first months of Ph.D, due to collaboration with the Université Paris-
Sud, by means of a Capes/COFECUB cooperation project, we have modified my thesis 
project resulting in the works presented in the previous nine chapters. 
 Although in a short period of time (around four months), summed to some results 
from the master period, the previous Ph.D project resulted in paper entitled 
“Stearylamine-Containing Cationic Nanoemulsion as a Promising Carrier to Gene 
Delivery”, published in the Journal of Nanoscience and Nanotechology.  
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brevet. L'encapsulation de ce dérivé dans 
une microémulsion est également décrite. 
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Abstract : The amphotericin B (AmB) is an 
old molecule used as golden standard for the 
treatment of diseases such as deep fungal 
infection and leishmaniasis. In spite of being 
in the market since the 1960’s, there is a lack 
of studies about the aggregation state of this 
drug into the carrier systems. Such an 
information gains importance when one 
knows that the self-association of the 
molecule plays an important role on the drug 
toxicity. 
This thesis was divided in four sections. In 
the first one, a revision on the literature was 
made in order to highlight the 
physicochemical characteristics of the drug 
and mainly the pharmaceutical strategies for 
AmB delivery. Among the strategies there is 
the solubilization of the drug into micelles. 
This strategy was studied in the second 
section, dedicated to the  
comparison of micellar systems available in 
the market and to the “super-aggregates” 
formation. Here we explained why it was not 
possible to produce “super-aggregates” from 
liposomes. 
The third section dealt with lipid emulsions: 
micro- and nano-emulsion; drug loading, 
aggregation state and applications on the 
treatment of fungal and leishmania 
infections were discussed in this section. 
The last section of this thesis was about the 
production of an AmB-soluble derivative. A 
patent for the production process was 
presented and finally, the derivative 
encapsulation into a microemulsion was 
conducted. 
 
 
 
